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Alveolar hypoxia is observed in a number of clinical settings, and is frequently 
associated with systemic effects, many of which present an inflammatory 
component. Reduction of alveolar PO2 in rats induces a rapid and widespread 
inflammatory response in mesentery, skeletal muscle and brain, characterized by 
increased microvascular levels of reactive oxygen species (ROS), increased 
leukocyte-endothelial adhesive interaction, extravasation of albumin and 
perivascular mast cell degranulation. There is substantial evidence that the 
systemic inflammation elicited by alveolar hypoxia is not triggered by the 
reduction of peripheral tissue PO2, but rather by a mediator(s) released from 
alveolar macrophages and transported by the circulation. The mediator activates 
local tissue mast cells which release inflammatory agents and activate the renin-
angiotensin system (RAS) to initiate the systemic inflammation. 
    The major objective of this study was to investigate the links between 
alveolar hypoxia, alveolar macrophages, resident tissue macrophages and mast 
cells to understand the mechanisms underlying the systemic inflammation. 
Our results showed that topical application of supernatant of hypoxic alveolar 
macrophages, but not of hypoxic peritoneal macrophages produced inflammation 
in the normoxic mesentery. Hypoxia induced a respiratory burst in alveolar, but 
not peritoneal macrophages. Cultured peritoneal mast cells did not degranulate 
with hypoxia. Immersion of mast cells in supernatant of hypoxic alveolar 
macrophages, but not in supernatant of hypoxic peritoneal macrophages, 
induced mast cell degranulaton.. These data suggest that alveolar macrophage-
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borne mediator activates mast cells and triggers the systemic inflammation 
induced by hypoxia, in which reduced systemic PO2 and activation of tissue 
macrophage do not play a role.  
Hypoxia induced release of   monocyte chemoattractant protein-1(MCP-1/CCL-
2), a mast cell secretagogue, from alveolar macrophages, but not peritoneal 
macrophages or mast cells. Further studies showed that alveolar macrophage-
borne MCP-1 played a central role in the inflammation: 1) Alveolar hypoxia 
produced a rapid increase in plasma MCP-1 concentration of conscious intact 
rats, but not of alveolar macrophage-depleted rats. 2) Degranulation occurred 
when mast cells were immersed in the plasma of hypoxic intact rats, but not of 
alveolar macrophage-depleted rats. 3) MCP-1 added to normoxic rat plasma and 
supernatant of normoxic alveolar macrophages produced concentration-
dependent degranulation of immersed mast cells. 4) MCP-1 applied to the 
mesentery of normoxic intact rats replicated the inflammation of alveolar hypoxia. 
5) The CCR2b receptor antagonist RS-102895 prevented the mesenteric 
inflammation of alveolar hypoxia in intact rats. Additional data suggested that a 
co-factor constitutively generated in alveolar macrophages and presented in 
normoxic body fluids is necessary for MCP-1 to activate mast cells at biologically 
relevant concentrations.  
    As previously seen in cremaster, the RAS is involved in the mesenteric 
inflammation of hypoxia. Demonstration of similar inflammatory pathways in both 
cremaster and mesentery provides further support to the idea of a circulating 
mediator initiating the inflammation of hypoxia. The previous findings in the 
vi 
 
cremaster were expanded in several ways: an involvement of NADPH oxidase as 
an RAS effector was shown. In addition, it was demonstrated that renin is 
expressed in rat peritoneal mast cells, and that renin from MCP-1/CCL2-
activated mast cells contributes to activation of tissue-specific RAS in 
inflammation induced by alveolar hypoxia. 
    In summary, the present studies provide substantial evidence in support of 
the idea that the systemic inflammatory response to alveolar hypoxia is initiated 
by an alveolar macrophage-borne MCP-1, which, in turn, activate local RAS via 
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Reduced alveolar PO2 is observed in a number of clinical settings, and is 
frequently associated with systemic effects, many of which present an 
inflammatory component. Reduction of inspired PO2 alveolar macrophage-
induced systemic inflammation has been documented in humans and in animal 
experiments. The major objective of this project was to characterize a novel 
phenomenon, namely the systemic inflammation initiated by alveolar 
macrophages activated by a reduction of alveolar PO2. Investigation of the links 
between alveolar macrophages, alveolar hypoxia, and systemic inflammation 
provided insights into the pathogenesis of the systemic effects of conditions 
associated with alveolar hypoxia. 
 
1.1  Alveolar hypoxia and systemic effects 
Hypoxia, as a result of impairments in one or more of the linked steps of the O2 
transport system, is a very serious and common feature of many diseases of 
cardiovascular and respiratory origin. Frequently, clinical conditions as well as 
experimental interventions associated with alveolar hypoxia are accompanied by 
systemic effects. These systemic effects include cachexia and muscle wasting 
(Agusti and Soriano, 2008; Wust and Degens, 2007) and the cardiovascular 
abnormalities (Eickhoff et al.) of chronic obstructive pulmonary disease (COPD), 
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the suboptimal erythropoiesis of pulmonary fibrosis (Tsantes et al.) and the 
cardiovascular complications of sleep apnea (Jelic et al., 2008; Morgan, 2007). In 
acute conditions, systemic responses with a possible inflammatory link include 
the multiple organ failure secondary to atelectasis (Kisala et al.), acute lung injury 
(Puneet et al., 2005; St John et al., 1993)，pulmonary contusion (Perl et al.) and 
the systemic inflammation of pneumonia (Fernandez-Serrano et al.). Alveolar 
hypoxia occurs also in healthy individual exposed to altitude. Rapid ascent to 
high altitude is increasingly frequent and may result in acute mountain sickness 
or high altitude cerebral edema (Basnyat and Murdoch). Although the role of 
inflammation in these cases remains unclear yet, the presence of elevated levels 
of circulating and tissue inflammatory markers (Beidleman et al., 2006; Hartmann 
et al., 2000; Klausen et al., 1997), and the effectiveness of dexamethasone, an 
anti-inflammatory steroid, in the treatment of acute mountain sickness (Basnyat 
and Murdoch, 2003; Michiels et al., 2000), suggest the contribution of an 
inflammatory component. 
Rats breathing 10% O2 show a rapid inflammatory response in mesentery, 
skeletal muscle and pial microcirculations within minutes of the onset of hypoxia. 
This response is characterized by increased levels of reactive oxygen species 
(ROS) (Wood et al., 1999a), mast cell degranulation (Steiner et al., 2003), 
leukocyte-endothelial adhesive interactions (Dix et al., 2003; Shah et al., 2003; 
Steiner et al., 2003; Wood et al., 1999b), and extravasation of albumin (Wood et 
al., 2000). Increased levels of ROS-dependent fluorescence occur within minutes 
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of the onset of hypoxia, and are observed in perivascular mast cells, the 
endothelial layer of postcapillary venules and the sites of leukocyte-endothelial 
adherence (Wood et al., 2000; Wood et al., 1999b). The magnitudes of the ROS-
dependent fluorescence intensity and the leukocyte-endothelial adhesive 
interactions are inversely related to the PO2 value (Steiner et al., 2002), and were 
significantly attenuated by the antioxidants SOD/catalase and lipoic acid (Wood 
et al., 1999a, 2000). Increasing microvascular NO levels by administration of a 
NO donor, spermine NONOate (sNO) or of the NO precursor L-arginine blocked 
the increases in ROS and in leukocyte-endothelial adhesive interactions induced 
by hypoxia (Steiner et al., 2002). This suggests that hypoxia is associated with a 
decrease in NO as well as an increase in ROS levels. NO levels could be 
reduced as a result of consumption by the elevated ROS; alternatively, NO 
generation could be decreased by reduced NO synthase (NOS) activity due to 
limitation of O2 substrate availability in hypoxia. However, if this was the case, it 
would be expected that administration of the substrate L-arginine would not be 
effective in restoring NO levels during hypoxia. The observation that 
administration of L-arginine and of sNO had the same effects, qualitatively and 
quantitatively, suggests that the decrease in microvascular NO levels is not the 






1.2   Alveolar hypoxia and mast cell activation  
Mast cell degranulation is a necessary event which provides the chemotactic 
gradient for the increased leukocyte-endothelial adhesive interactions of hypoxia 
(Steiner et al., 2003). Prevention of mast cell degranulation with cromolyn, a 
mast cell stabilizer, attenuates all of the markers of inflammation (Shah et al., 
2003; Steiner et al., 2003). The inflammatory cascade includes activation of the 
local renin-angiotensin system (RAS): the increased leukocyte-endothelial 
adherence and vascular permeability observed in skeletal muscle during alveolar 
hypoxia are attenuated by inhibition of angiotensin converting enzyme (ACE) and 
by blockade of angiotensin II (Ang II) receptors (Gonzalez et al., 2007b). 
A series of observations suggests that the key initial event of the inflammatory 
response, the activation of mast cells, is not triggered by the reduced PO2 of the 
environment surrounding the mast cells, but rather by an agent(s) released by 
alveolar macrophages into the circulation. 
First, selective reduction of tissue microvascular PO2 does not induce 
inflammation unless it is accompanied by alveolar hypoxia. Cremaster 
microvascular PO2 (CmvPO2), measured using a phosphorescence decay assay 
(Shah et al., 2003), was selectively reduced in rats breathing room air. Cremaster 
hypoxia was induced either by mechanical restriction of cremaster blood flow 
(Shah et al., 2003), or by in vivo equilibration of the cremaster with 5% CO2/95% 
N2 (Dix et al., 2003; Shah et al., 2003) in the presence of normal systemic arterial 
and alveolar PO2. Although CmvPO2 decreased to levels comparable to those 
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seen in rats breathing 10% O2, neither of these interventions produced mast cell 
degranulation or leukocyte-endothelial adherence in cremaster post-capillary 
venules. On the other hand, cremaster mast cell degranulation and leukocyte 
adherence occurred when the animals breathed 10% O2 and CmvPO2 was 
maintained at a higher than normal level (Dix et al., 2003; Shah et al., 2003). One 
possible explanation for these results, among other alternatives, is that mast cell 
degranulation is triggered by an agent released from a distant site. 
Second, if a putative mediator released from a distant site is transported by the 
systemic circulation, it would be expected that plasma obtained from hypoxic 
animals would elicit inflammation in normoxic tissues. Plasma obtained from 
conscious rats breathing 10% O2 for 5 min produced mast cell degranulation, 
leukocyte-endothelial adherence, and extravasation of albumin when applied to 
the cremaster muscle of normoxic rats (Orth et al., 2005). The inflammatory 
effect is specific for hypoxic rat plasma since plasma from normoxic animals did 
not exert any effect on the cremaster microcirculation. The inflammation is not 
triggered by mediators released from activated mast cells or adherent leukocytes 
into the plasma of the donor rat: pretreatment of the donor with cromolyn, which 
blocks alveolar hypoxia-induced mast cell degranulation and leukocyte 
adherence (Steiner et al., 2003), did not attenuate the response to hypoxic rat 
plasma. The inflammatory agent contained in hypoxic rat plasma is not originated 
in blood cells, since plasma separated from blood equilibrated in vitro with 
hypoxic gas mixtures did not produce inflammation (Orth et al., 2005). 
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1.3  Alveolar macrophage activation and systemic inflammation 
Alveolar hypoxia induces lung inflammation, and alveolar macrophages play 
an important role in the modulation of this phenomenon. Rats breathing 10% O2 
for periods ranging from 1 to 8 h show extravasation of albumin and increased 
pulmonary expression of HIF-1α, NF-κB, and pro-inflammatory cytokines; these 
markers are attenuated by elimination of alveolar macrophages (Beck-Schimmer 
et al., 2001; Leeper-Woodford and Detmer, 1999; Madjdpour et al., 2003; 
VanOtteren et al., 1995). Hypoxia leads to upregulation of the expression of 
neurokinin-1 receptors in alveolar macrophages and epithelial cells (Zee et al., 
2006). Activation of these receptors leads to inflammatory responses mediated 
by cytokines IL-1, IL-6, and TNF-α (Lotz et al., 1988; Zee et al., 2006). 
Furthermore, alveolar macrophages have been implicated in the synergistic 
effects of hypoxia on pathogen-induced lung inflammation (Agorreta et al., 2005; 
Vuichard et al., 2005). 
In addition to the well known pulmonary effects of alveolar macrophage 
activation with hypoxia and other stimuli, there is mounting evidence that 
activation of alveolar macrophages has substantial extrapulmonary effects. An 
example is the systemic microvascular response to particulate matter inhalation. 
Epidemiological studies have demonstrated a correlation between environmental 
air pollution and cardiovascular morbidity (Simkhovich et al., 2008), and clinical 
and experimental studies have shown that phagocytosis of fine particles by 
alveolar macrophages leads to pulmonary inflammation with increased number of 
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activated alveolar macrophages (Tamagawa et al., 2008). This is accompanied 
by elevated levels of circulating cytokines, systemic inflammation, and 
microvascular endothelial dysfunction in the systemic circulation (Ishii et al., 
2005; Nemmar et al., 2005; Nurkiewicz et al., 2006; van Eeden et al., 2001). It 
has been suggested that following phagocytosis of particulate matter, cytokines 
released by activated alveolar macrophages act on the bone marrow to mobilize 
platelets and leukocytes which stimulate the release of acute phase proteins and 
lead to systemic inflammation (Fujii et al., 2002). 
Alveolar macrophages are necessary for the inflammation of alveolar hypoxia 
which was demonstrated by three lines of evidence (Gonzalez et al., 2007a): 
first, depletion of alveolar macrophages by tracheal instillation of clodronate-
containing liposomes blocked the mast cell degranulation, the increased 
leukocyte-endothelial adherence and the extravasation of albumin that follows 
alveolar hypoxia in intact rats. Second, plasma obtained from hypoxic, alveolar 
macrophage-depleted rats did not elicit inflammation when applied to the 
normoxic cremaster; third, supernatant of primary cultures from alveolar 
macrophages exposed to 10% O2 induced mast cell degranulation and 
leukocyte-endothelial adherence when applied topically onto the normoxic 
cremaster. A non-specific effect was ruled out by the observation that 
supernatant of alveolar macrophages cultured in normoxia failed to exert any 
inflammation on the cremaster microcirculation. The inflammation initiated by 
hypoxic alveolar macrophage supernatant shares common pathways with that 
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secondary to alveolar hypoxia in intact animals, since both are attenuated by 
blockade of the RAS (Gonzalez et al., 2007a; Gonzalez et al., 2007b). 
 
1.4   Mast cell activation and RAS 
Plasma from hypoxic rats produces not only increased venular leukocyte-
endothelial interactions and mast cell activation, but also produced local arteriolar 
vasoconstriction in the normoxic cremaster (Gonzalez et al., 2007a; Orth et al., 
2005). Alveolar hypoxia, induced by 10% O2 breathing, produced an initial 
arteriolar vasoconstriction in skeletal muscle which is followed by vasodilation 
(Orth et al., 2005). On the other hand, non-selective Ang II antagonists and ACE 
inhibitors attenuate the inflammation induced by alveolar hypoxia in intact rats 
(Gonzalez et al., 2007b). These results suggest a participation of the RAS in the 
inflammatory cascade initiated by alveolar hypoxia. In addition to the circulating 
RAS, local tissue RAS plays an important role in several pathophysiological 
processes, including cardiovascular inflammation (Paul et al., 2006; Peters and 
Unger, 2007; Sironi et al., 2005). Ang II is a potent vasoconstrictor implicated in 
inflammatory processes in the cardiovascular system (Carey and Siragy, 2003; 
Cheng et al., 2005; Ferrario and Strawn, 2006) which can cause increased 
leukocyte-endothelial interactions and leukocyte recruitment, increased vascular 
permeability, and eventually tissue remodeling (Cheng et al., 2005; Strawn and 
Ferrario, 2002; Weir and Dzau, 1999). Similar to systemic hypoxia, Ang II 
stimulates leukocyte-endothelial interactions in postcapillary venules via 
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generation of reactive O2 species (Suzuki et al., 2006); these effects can be 
blocked by antioxidant administration (Wood et al., 1999a). The inflammatory 
response to alveolar hypoxia, as well as the inflammation produced by plasma 
from hypoxic rats, can be blocked by ACE inhibitor, and by Ang II receptor 
blocker (Gonzalez et al., 2007b).  
The following evidences suggest that mast cells are involved in RAS activation: 
Cromolyn, a mast cell stabilizer, abolish the inflammatory response of hypoxic rat 
plasma on normorxic cremaster, which suggests that mast cell activation is 
necessary for the inflammation originated by hypoxic rat plasma (Gonzalez et al., 
2007b). The inflammation produced by hypoxic rat plasma via mast cell is 
blocked by Ang II receptor blockade and by ACE inhibitors (Gonzalez et al., 
2007b); on the other hand, topical Ang II produces inflammation in the normoxic 
cremaster without activating mast cells; and the inflammatory effects of Ang II are 
not blocked by cromolyn (Gonzalez et al., 2007b). Finally, the inflammation 
produced by stimulation of mast cells with compound 48/80, a mast cell 
secretagogue, is attenuated by ACE inhibition and Ang II receptor blockade. The 
result obtained from intact animals suggest that the activation of RAS occurs 
downstream of mast cell degranualtion. 
The exact mechanisms underlying the activation of RAS by mast cells remain 
uncertain. Mast cells from some species contain chymases which act as ACE to 
convert Ang I to Ang II; moreover, renin contained in mast cells may initiate the 
RAS cascade. Consistent with this, a recent study demonstrated that renin 
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released from cardiac mast cell activates the RAS during ischemia/reperfusion 
(Silver et al., 2004).  
In summary, previous data from our laboratory support the idea that a putative 
mediator released from alveolar macrophages during alveolar hypoxia activates 
perivascular mast cells, which, in turn initiate the inflammatory cascade by 
activating the RAS system. 
The diagram below represents schematically the status of our understanding of 
this subject at the moment that the research described here was initiated: 
 
AMØ: Alveolar macrophage 
Hx: Hypoxia 
AII RB: Angiotensin II receptor blocker 





2.1 Bronchoalveolar lavage (BAL) and culture of alveolar macrophage 
(Chao et al., 2009a; Gonzalez et al., 2007a) 
Sprague-Dawley rats (300–350g) were anesthetized with pentobarbital sodium 
(40 mg/kg i.p.). A PE-50 catheter was placed in the jugular vein, a tracheotomy 
was performed, and a PE-240 catheter was inserted in the trachea. An overdose 
of sodium pentobarbital (150 mg/kg i.v.) was administered to euthanize the 
animals. Phosphate-buffered saline (PBS, 10 ml) was injected slowly into the 
lungs; the liquid was then removed and transferred into a plastic tube. This 
operation was repeated 10 times. The fluid collected was centrifuged at 1,500 
rpm for 10 min. The cell pellets were pooled and resuspended in 2 ml of 
Dubelcco’s Modified Eagle’s Medium (DMEM) with 10% serum containing 
penicillin (100 U/ml) and streptomycin (100 μg/ml). A small sample of the 
suspension was obtained for cell counting in a hemocytometer.   
Approximately 7 million alveolar macrophages are typically obtained from each 
rat using this procedure. Excluding variable amounts of red blood cells, which 
were eventually washed out (see below), the cells recovered were essentially all 
alveolar macrophages. The cells were plated in a T-25 sterile flask at 37°C and 
equilibrated with 5% CO2 in air for 45 min. At this moment, the alveolar 
macrophages, but not the red blood cells, were firmly adherent to the flask. The 
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supernatant was discarded with a pipette, which resulted in elimination of red 
blood cells. The adherent alveolar macrophages were washed twice with 2 ml 
serum-free DMEM. After washing, 2 ml of serum-free DMEM were added and the 
flask was placed in a cell culture incubator at 37°C.  
The cell culture was equilibrated with humidified gas mixtures via an 18-gauge 
needle placed on the flask’s cap and connected to the gas source. Care was 
taken to place the tip of the needle a few mm above the surface of the medium 
so as not to disturb the culture. Incubation with humidified gas mixtures with 
nominal concentrations of O2 (all gases had 5% CO2 with the balance made up 
with N2) was maintained for 30 min. Using this system, stable PO2 values are 
reached within 2 minutes. After 30 min of equilibration, the supernatant was 
either used immediately or removed and frozen at -80°C. In the latter case, the 
supernatant was thawed on the day of the experiment. In either case, when the 
30 minutes equilibration with the test gas mixture was finished and the 
supernatant removed, 0.4 % Trypan Blue (0.2 ml) was added to the culture flask. 
Within 30 minutes of addition of Trypan Blue, photographs were obtained from 5 
different areas of the culture, containing approximately 200 cells each. The cells 
were counted to estimate cell viability as determined by exclusion of Trypan Blue. 
 
2.2   Peritoneal lavage and culture of isolated peritoneal mast cells 
(Chao et al., 2009a; Poole and Zetter, 1983) 
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Peritoneal mast cells were harvested by lavage of the peritoneal cavity. 
Sprague-Dawley rats (250–300g) were anesthetized with ketamine 45 mg/kg 
i.m., atropine 0.4 mg/kg i.m., and a PE-50 catheter was placed in the jugular 
vein. Twenty ml of DMEM with 10% serum containing penicillin (100 U/ml), 
streptomycin (100 μg / ml) and heparin (5 U/ml) were injected into the peritoneal 
cavity, followed by gentle massage and recovery of fluid into cooled 
polypropylene tubes. Usually, cells obtained from 2 rats were pooled and used 
for one primary culture. Once the lavage was completed, the rats were 
euthanized with an overdose of sodium pentobarbital (150 mg/kg i.v.).  
The cells were centrifuged at 400g for 15 min at room temperature and 
washed twice with serum-free DMEM. Cell pellets were resuspended in 0.75 ml 
serum-free DMEM, and macrophages were separated from mast cells by 
differential centrifugation using a Percoll solution as described before. Mast cells 
isolated by this procedure exceed 95% in purity. 
The separated mast cells were resuspended in 2ml of DMEM with 10% serum 
containing penicillin (100 U/ml), streptomycin (100 μg/ml) and plated in a T-25 
sterile flask at 37°C in 10% O2-5% CO2 - 85% N2 for 45 min. The mast cells were 
collected by centrifugation at 3000 rpm for 2 minutes. The supernatant was 
discarded with a pipette and resuspended in 2 ml of serum-free DMEM. The cell 
culture was equilibrated with humidified gas mixtures (10% O2-5% CO2-85% N2) 
via an 18-gauge needle placed on the flask’s cap. Forty five min later, aliquots 
containing 0.4×106 cells each were placed into centrifuge tubes and centrifuged 
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at 3000 rpm for 2 minutes. The supernatants were discarded and replaced with 
0.4ml medium, plasma or alveolar macrophage supernatant, depending on the 
experimental protocol. The cells were incubated for 20 minutes and then 
centrifuged at 3000 rpm for 2 minutes. The cells were resuspended in 40μl of 
ruthenium red (50 μg/ml) to yield cell concentration of 107cell/ml. The percentage 
of degranulated mast cells was checked with cell smear in a Nikon TE2000-S 
microscope. Photographs were obtained from 5 different areas of the slide, 
containing approximately 20 cells each. 
 
2.3 Selective depletion of alveolar macrophages (Gonzalez et al., 2007a; 
Van Rooijen and Sanders, 1994) 
Tracheal instillation of clodronate-containing liposomes was used to deplete 
alveolar macrophages in rats. Liposomes were composed of phosphatidylcholine 
and cholesterol in a 6-to-1 molar ratio and contained either clodronate or 
phosphate-buffered saline (PBS). Clodronate was a gift of Roche Diagnostics 
(Mannheim, Germany). It was encapsulated in liposomes as described 
previously.  
Male Sprague-Dawley rats (300–350 g) were anesthetized with sodium 
pentobarbital (40 mg/kg i.p.), and the trachea was exposed with a midline 
incision. The animals were randomly assigned to either an alveolar macrophage 
depletion group, which received liposomes containing clodronate, or a control 
group, in which the rats were administered PBS-containing liposomes. The 
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animals were positioned at an angle of 30° head up, and 350 μl of a solution 
containing 250 mg clodronate liposomes/ml was injected between the tracheal 
cartilages with a 28-gauge needle. The skin incision was sutured, and the 
animals remained in the tilted position for 30 min, after which they were returned 
to their cages. The animals recovered uneventfully, and experiments were 
carried out 4 days after liposome administration.  
The effectiveness of clodronate-containing liposomes was estimated by 
measuring the number of alveolar macrophages recovered in BAL described in 
section 1. The animals were studied four days after liposome administration. At 
the end of the experiment, the animals were anesthetized with sodium 
pentobarbital 40 mg/kg i.v, and 5 ml of blood removed into a heparinized syringe. 
Plasma was obtained by centrifugation and used for the mast cell immersion 
experiments. After blood removal, the animals were euthanized with 150mg/kg 
sodium pentobarbital, and BAL was carried as described above. Alveolar 
macrophages recovered in BAL were counted in a hemocytometer.  
 
2.4  Exposure of conscious rats to hypoxia (Gonzalez et al., 2007a) 
Three days after injection of clodronate or PBS liposomes the rats were 
anesthetized with pentobarbital sodium (40 mg/kg i.p.). PE-50 catheters were 
placed in the carotid artery and external jugular vein, tunneled subcutaneously, 
exteriorized at the back of the neck, and flame sealed. Twenty four hours later, 
the rats were placed into a Lucite chamber in which 10% O2-90% N2 was 
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circulated. Before and at 5, 30 and 60 min of exposure to hypoxia, a 1-ml blood 
sample was obtained in a 5-ml syringe coated with heparin (1,000 USP units/ml), 
and the blood was centrifuged at 3000 rpm for 10 min. Plasma was separated 
and stored at -80°C. Withdrawn blood was replaced after sampling by blood 
obtained from donor rats.   
 
2.5 Intravital Microscopy (Chao et al., 2009a; Wood et al., 1999a) 
Male Sprague-Dawley rats (250–300 g) were anesthetized with ketamine 45 
mg/kg, atropine 0.4 mg/kg i.m. PE-50 catheters were placed in the jugular vein 
and carotid artery for injection of solutions and measurement of arterial blood 
pressure. The abdomen was opened via a midline incision and the ileo-cecal 
portion of the intestine was gently drawn out, exteriorized, and mounted on a 
transparent plastic stage. The intestinal loop was covered with Saran wrap to 
prevent drying of the tissue and to minimize the effect of ambient oxygen on the 
mesenteric microcirculation. The Saran wrap cover was briefly lifted when 
solutions were applied topically to the mesentery.The animals were covered with 
a thermal blanket to maintain rectal temperature at 37°C.  
The mesentery microcirculation was observed by transillumination using an 
inverted microscope. Color images of the microcirculation were shown in a video 
monitor by a camera mounted on the microscope. The images were recorded on 
a videocassette recorder with a time-date generator for off-camera analysis. 
Centerline red blood cell velocity was measured using an optical Doppler 
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velocimeter. Average red blood cell velocity was calculated as centerline 
velocity/1.6. Venular diameter was measured using a video caliper. Single 
unbranched post-capillary venules, with a diameter of 20-40 μm, length of ~200 
μm, less than 3 adherent leukocytes /100 μm, and a steady venular blood 
velocity of at least 2 mm/sec were selected for observation in this study. 
Adherent leukocytes were defined as those remaining stationary for 30 sec. 
Leukocyte endothelial adherence (LEA) was expressed as number of adherent 
leukocytes / 100 μm of venule length. Ruthenium red (5 mg/100 ml) was applied 
topically to document in vivo mast cell degranulation. The mast cell images were 
converted to digitized grayscales and phase-inverted. The relative light intensity 
of each mast cell within the field of view was measured using the AnaliSYS 
Software System, and the extent of ruthenium red uptake was estimated from the 
gray scale intensity value and expressed in arbitrary units. At least 5 mast cells 
were analyzed in each field of observation. At the end of the experiment, the rats 
were killed with an overdose of sodium pentobarbital, 150 mg/kg i.v. 
 
2.6 Statistics 
  Data are means ±SEM. Each preparation served as its own control, with the 
data obtained after a given treatment compared with that obtained during the 
control period. Significance was established using a t test for paired values. 
Intergroup comparisons were made with a one way ANOVA with the Bonferroni 




Interaction between alveolar macrophages and mast 
cells in the inflammatory response induced by hypoxia  
3.1  Introduction 
Alveolar hypoxia, induced by reduction of inspired PO2, initiates a rapid and 
widespread inflammatory response in mesentery (Wood et al., 1999b), skeletal 
muscle (Dix et al., 2003; Shah et al., 2003) and brain (Mc Donald and Wood, 
2003) of rats. The inflammation is characterized by increased microvascular 
levels of ROS (Wood et al., 1999a), perivascular mast cell degranulation (Dix et 
al., 2003; Shah et al., 2003; Steiner et al., 2003), increased leukocyte-endothelial 
adhesive interactions (Wood et al., 1999b), and extravasation of albumin (Wood 
et al., 2000).  
Studies in the cremaster microcirculation suggest that the inflammation elicited 
by alveolar hypoxia is not triggered by the reduction of cremaster PO2, but rather 
by a mediator released from a distant site and transported by the circulation. This 
idea is supported by two lines of evidence: first, selective reduction of cremaster 
PO2 does not produce mast cell degranulation and inflammation in the cremaster 
microcirculation unless alveolar PO2 is also reduced (Dix et al., 2003; Shah et al., 
2003); second, plasma obtained from hypoxic rats applied to the normoxic 
cremaster produces an inflammatory response similar to that elicited by alveolar 
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hypoxia (Orth et al., 2005). The response to hypoxic rat plasma is not due to 
inflammatory mediators released into plasma by activated mast cells or adherent 
leukocytes of the donor rat; furthermore, the agent(s) responsible for the 
inflammation is not generated by blood cells (Orth et al., 2005). Further 
investigation showed that the putative mediator activates mast cells and initiates 
an inflammatory cascade that includes activation of the renin-angiotensin system 
(RAS) (Gonzalez et al., 2007b). 
A role for alveolar macrophages as a source of the putative mediator is 
supported by the findings that alveolar macrophage depletion in vivo attenuates 
the inflammatory response to alveolar hypoxia, and that supernatant of alveolar 
macrophages cultured in hypoxia induces mast cell degranulation and 
inflammation in normoxic cremaster muscle (Gonzalez et al., 2007a). Similar to 
the inflammation elicited by alveolar hypoxia (Gonzalez et al., 2007b), the 
response to alveolar macrophage supernatant was abrogated by pretreatment 
with cromolyn, a mast cell stabilizer, and with Ang II receptor antagonists 
(Gonzalez et al., 2007a). 
The present experiments were designed to provide evidence of a direct link 
between the activation of alveolar macrophages by the reduced alveolar PO2 and 
the degranulation of tissue mast cells which initiates the inflammation of hypoxia. 
We reasoned that if an alveolar macrophage-borne mediator(s) triggers the 
inflammation by activating mast cells, reduced PO2 would not directly activate 
primary mast cell cultures, but, on the other hand, these cells would degranulate 
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when placed in contact with supernatant of hypoxic alveolar macrophages. 
Furthermore, we hypothesized that hypoxia would not directly activate isolated 
resident tissue macrophages, and that mast cells exposed to supernatant of 
resident tissue macrophages cultured in hypoxia would not undergo 
degranulation. The results confirm our hypothesis that the inflammation of 
alveolar hypoxia is triggered by a mediator(s) released by activated alveolar 
macrophages, and rule out possible contributions of local hypoxia and of resident 
tissue macrophages in the initiation of the inflammation. A mast cell 
secretagogue, monocyte-chemoattractant protein-1, was identified as a possible 
candidate for the putative mediator of hypoxia-induced systemic inflammation. 
The phenomenon described here highlights a systemic effect of alveolar 
macrophage activation, and could provide a possible pathogenic mechanism to 
explain the systemic consequences of conditions associated with reduced 
alveolar PO2. 
 
3.2  Methods 
The general methods and techniques utilized are described in detail in chapter 
2.  
The experiments described below included in vivo studies in which supernatant 
of primary cell cultures as well as pharmacological agents were applied topically 
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to the mesentery of normoxic rats, and in vitro studies carried out in primary cell 
cultures. 
Alveolar macrophages in an intact animal are normally exposed to a higher 
PO2 than peritoneal macrophages or peritoneal mast cells, and this difference 
subsists in conditions of hypoxia. Accordingly, humidified gas mixtures for the cell 
culture experiments were used with nominal concentrations of 21, 10, and 0% 
O2. All gas mixtures contained 5% CO2 with the balance made up with N2. These 
gas mixtures provided PO2 values that encompass the range observed in vivo, 
from normoxic to hypoxic conditions, in the cell types studied here. The PO2 
attained in the liquid phase during gaseous equilibration in an open system 
depends on the efficacy of the equilibration system. In the present experiments, 
the cell cultures, placed in an incubator at 37oC, were gassed via a needle 
inserted in the cap of the culture dish and connected to the gas source. Care was 
taken to place the tip of the needle a few mm above the surface of the culture 
medium so as to not disturb the culture. In order to directly determine the efficacy 
of the equilibrating system, PO2 of the medium was measured directly in some of 
the experiments using a phosphorescence decay method (Lo et al., 1996). This 
technique is currently employed in our laboratory to measure microvascular PO2 
of intact animals (Dix et al., 2003; Shah et al., 2003). The actual supernatant PO2 
values were (Torr, mean ± SEM): 0% O2: 4.8 ± 0.8, and 10 % O2: 65.3 ± 0.9. 
These values were attained within 2-3 minutes of equilibration. Exposure to 21% 
O2 produced PO2 values outside the range of the method (>100 Torr). Alveolar 
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macrophages may be exposed in vivo to PO2 of ~ 65 Torr in moderate cases of 
hypoxia. In contrast, peritoneal macrophages and mast cells exposed to 10% O2 
will be in an environment which is at the high end of the PO2 values observed in 
vivo. On the other hand, PO2 of ~ 5 Torr is the value to which peritoneal 
macrophages, mast cells and other systemic tissue cells would be exposed in a 
rat breathing 10% O2 (Dix et al., 2003; Shah et al., 2003). 
 
3.2.1  Measurement of H2O2 in supernatant of alveolar and peritoneal 
macrophages 
An electrochemical detection system (Apollo 4000, World Precision 
Instruments) was used to determine H2O2 concentration in 0.3 ml aliquots of 
supernatant of alveolar and peritoneal macrophages isolated and cultured on the 
day of measurement. Measurements were carried out in samples removed at 15 
min intervals using an H2O2-sensitive electrode at 37° C. After measurement, the 
sample was returned to the culture dish. When the experiments were finished, 2 
ml of a solution of 0.4% Trypan Blue was added to the culture and mixed for 2 
minutes. Photographs of 5 different areas of the culture, containing 
approximately 200 cells each, were obtained within 30 min of Trypan Blue 






3.2.2  Measurement of inflammatory mediators 
The effect of hypoxia on supernatant levels of several cytokines and 
chemokines was investigated by initially screening cytokine and chemokine 
levels using a multianalyte ELISA Array (SABiosciences Corporation). Agents 
investigated in the initial screen included: Interleukins-1β, -4, -6, -10, -12, -17α; 
IFN-γ, TNF-α, Transforming Growth Factor-B1, Monocyte Chemoattractant 
Protein -1 (MCP-1), and Macrophage Inflammatory Protein (MIP) -1α and -1β. 
The initial screen was followed by individual assay (Single Analyte ELISA, 
SABiosciences Corporation) to determine levels of MCP-1 in supernatant of 
alveolar macrophages, peritoneal macrophages, and peritoneal mast cells. 
 
3.3   Results 
3.3.1   EXPERIMENTS IN THE MESENTERIC MICROCIRCULATION 
All experiments of this series had the same format: after a 30 min control 
period, ~0.5 ml of supernatant or of a pharmacological agent was distributed 
evenly over the mesentery. The microcirculation was observed for an additional 
30 min. The supernatants used had been frozen and were thawed at 37oC 
immediately before use. 
Effect of alveolar or peritoneal macrophage supernatant applied on the 
mesentery of normoxic rats 
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Supernatant of alveolar macrophages which had been equilibrated with 10% 
O2 produced mast cell degranulation and leukocyte-endothelial adherence 
(Figure 1A) (N = number of rats studied = 5). In contrast, neither supernatant 
from alveolar macrophages equilibrated with 21 % O2 (Figure 1B, N=5) or from 
peritoneal macrophages equilibrated with 0% O2, (Figure 1C, N=5) produced 
mast cell degranulation or leukocyte-endothelial adherence. 
 
Figure 1: Effect of topical application of AMØ and PMØ supernatant on the mesentery  
Top: Representative microphotographs of the mesenteric microcirculation after topical application 
of supernatant hypoxic alveolar macrophages (A), normoxic alveolar macrophages (B), and 
hypoxic peritoneal macrophages (C). The large dots are used to align the optical Doppler 
velocimeter and occasionally they are moved to obtain a better image of the leukocyte-endothelial 
interface for photographs. The red arrows point to the mast cells; the blue arrows identify 
adherent leukocytes. Bottom: average values of leukocyte-endothelial adherence (LEA) as 
assessed by number of leukocytes /100 μm, and intensity of mast cell degranulation (MCD) in 
arbitrary units. C and E: mean ± SEM of values at the end of the control and the experimental 





3.3.2   EXPERIMENTS IN PRIMARY CELL CULTURES 
H2O2 release by isolated alveolar and peritoneal macrophages 
All the experiments in this series had the same format: after a 45 minute period 
of equilibration with 21% O2 for alveolar and 10% O2 for peritoneal macrophages, 
the cultures were equilibrated for 60 min with the experimental gas mixture. 
Samples for supernatant H2O2 concentration measurement were obtained at the 
end of the normoxic control period and every 15 min thereafter. 
Table 1 shows the changes in supernatant H2O2 concentration with respect to 
their respective controls in the different groups. Under control conditions (21% 
O2), alveolar macrophage supernatant H2O2 concentration averaged 0.23 ± 0.05 
nM/106 cells, without significant differences among groups. Continuation of 
exposure to 21% O2 for one additional hour resulted in a gradual decrease in 
H2O2 concentration of the supernatant. Hypoxia (nominal 10% O2 and 0% O2) 
produced a significant net increase in alveolar macrophage supernatant H2O2 
concentration. The increase was significantly higher when the nominal O2 
concentration of the equilibrating gas mixture was 0% (actual PO2 ~ 5 Torr) than 
when equilibration was carried out with 10% O2 (actual PO2 ~ 65 Torr). The 
increase was transitory, reaching a peak at 15 min of equilibration, and gradually 
returning towards control. The increase in supernatant H2O2 produced by 
equilibration with 10% O2 was blocked by pretreatment with PEG catalase. 
Viability of alveolar macrophages, assessed by Trypan Blue exclusion at the end 
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of the experiments, was higher than 95% and was not influenced by the PO2, 
even when it reached values as low as ~ 5 Torr. 
 
Table 1: Effects of hypoxia on H2O2 release by alveolar and peritoneal macrophages 
Cell type 
% O2 Supernatant ∆[H2O2] (nM/10
6 cell) 


































































 Changes in the concentration of H2O2 with respect to the control: each value (N=5) is the 
average of the value at a given time minus the corresponding control. * P<0.05 vs. corresponding 
normoxic control. 
 
Average peritoneal macrophage supernatant H2O2 concentration under control 
conditions (10% O2) was 0.31 ± 0.05 nM/10
6 cells, which was not significantly 
different from that observed in alveolar macrophages under control conditions 
(21% O2). However, in contrast with alveolar macrophages, equilibration of 
peritoneal macrophages with 0% O2 was not accompanied by H2O2 release into 
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the supernatant. Cell viability at the end of 1 hour of equilibration was also 
approximately 95%, and was not influenced by the supernatant PO2.  
Because H2O2 activates mast cells and induces inflammation, additional 
experiments in the mesenteric microcirculation were carried out to determine 
whether the small amount of H2O2 present in the alveolar macrophage 
supernatant after 30 minutes of hypoxia could be responsible for the 
inflammatory response illustrated in Figure 1 A, where supernatant of alveolar 
macrophages equilibrated with 10% O2 was applied topically on the mesentery. 
Topical application of a solution of 10 nM H2O2, a concentration over 5 fold 
higher than that observed in the alveolar macrophage supernatant at 30 minutes 
of 10% O2 equilibration, did not increase leukocyte-endothelial adherence or 
mast cell degranulation above that of the untreated controls (compare figures 
Figure 2A and 2B). Only when a solution with a concentration of 10 μM was 
applied did leukocyte-endothelial adherence and mast cell degranulation become 




Figure 2: Effect of topical H2O2 on the normoxic mesentery 
Top: representative microphotographs of the mesenteric microcirculation illustrating the effect 
of topical application of H2O2. A: untreated; B: after application of 10 nM H2O2 and C: after 
application of 10 μM H2O2. Since H2O2 bleaches ruthenium red, the photographs were taken after 
the H2O2 was washed out from the surface, after which ruthenium red was applied. Bottom: 
average values of LEA as assessed by number of leukocytes /100 μm, and intensity of MCD in 
arbitrary units. * P<0.01 vs. corresponding normoxic control. N=5 in all cases. 
 
Effect of hypoxia on peritoneal mast cell degranulation 
Fresh peritoneal mast cell cultures (N = number of cell cultures studied = 5, 
Figure 3) were successively exposed to gas mixtures with 10 and 0% O2, and 0% 
O2 plus C48/80. After 30 min of exposure to each condition, a small sample (5-10 
μl, ~20,000 cells / μl) was removed and mixed with an equal volume of a solution 
of ruthenium red to assess mast cell degranulation. Exposure of peritoneal mast 
cells to 0% O2 did not significantly increase uptake of ruthenium red from the 
levels observed during normoxic equilibration (compare Figure 3A and 3B). 
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Addition of C48/80 during hypoxia to cells obtained from the same cultures 
induced complete mast cell degranulation (Figure 3C), indicating that the hypoxic 
mast cells could respond normally to a general secretagogue. 
 
 
Figure 3: Effect of hypoxia on mast cell degranulation 
Representative microphotographs of primary mast cell cultures. The cells represented in 
photographs A-C were obtained from the same primary culture. The data on top of each 
photograph is the mean ± SEM of the percent of MCD in 5 separate experiments. 
 
Interactions between isolated mast cells, alveolar macrophages and peritoneal 
macrophages 
In these series, mast cells cultured in 10% O2 were centrifuged, and the pellet 
suspended in supernatant removed from fresh primary cell cultures of alveolar or 
peritoneal macrophages. The supernatants contained no macrophages. The 
mast cells resuspended in macrophage supernatant were equilibrated with 10% 
O2 in all cases. 
Suspension of isolated mast cells in supernatant of alveolar macrophages 
which had been cultured in normoxia did not induce mast cell degranulation 
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(Figure 4A; N = number of cell cultures studied = 5); on the other hand, 
suspension in supernatant of alveolar macrophages cultured in hypoxia (10% O2) 
significantly increased mast cell degranulation (Figure 4B, N=5). In contrast, 
suspension of mast cells in supernatant of peritoneal macrophages which had 
been incubated with 0% O2, failed to produce mast cell degranulation (Figure 4C, 
N=5).  
 
Figure 4: Effect of immersion of mast cells in supernatant of alveolar or peritoneal 
macrophages 
Mast cells obtained for the same culture were immersed in supernatant of alveolar 
macrophages that had been equilibrated with 21% O2 (A), 10% O2 (B), or peritoneal 
macrophages equilibrated with 0% O2. The supernatants contained no macrophages and after 
mast cell immersion were equilibrated with 10% O2. The data on top of each photograph is the 
mean ± SEM of the percent of degranulated mast cells in 5 separate experiments. 
 
Effects of hypoxia on selected cytokine levels 
Of all the agents screened in the supernatant of alveolar macrophages using a 
multi-analyte ELISA array (IL-1β, -4, -6, -10, -12 and 17α, IFN-γ, MCP-1, TNF-α, 
and MIP-1α and -1β), only MCP-1 showed a marked increase with hypoxia within 
the time frame of these experiments. Subsequent individual ELISA assays using 
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a specific antibody showed that MCP-1 increases almost four-fold in the 
supernatant of alveolar macrophages exposed to hypoxia, compared to the 
normoxic control (Figure 5). In contrast, equilibration with nominal 0% O2 does 
not elicit release of MCP-1 from peritoneal macrophages or mast cells (Figure 5). 
































Figure 5: Effect of hypoxia on the release of MCP-1 by alveolar macrophages. 
Supernatant monocyte chemoattractant protein-1 concentration of primary cultures of alveolar 
macrophages, peritoneal macrophages, and peritoneal mast cells, exposed to 30 min of hypoxia 
or normoxia. * P<0.01 vs. corresponding normoxic control. N=5 in each case. 
 
3.4   Discussion 
The central findings of these experiments are the following: 1. Supernatant of 
hypoxic alveolar macrophages elicited inflammation in the normoxic mesentery, 
while supernatant of peritoneal macrophages equilibrated with even lower PO2 
values had no inflammatory effect. 2. Hypoxia activated primary cultures of 
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alveolar, but not of peritoneal macrophages. 3. Mast cells in primary cultures did 
not degranulate when exposed to hypoxia; however, degranulation occurred 
when mast cells were placed in contact with supernatant of hypoxic alveolar 
macrophages, but not of hypoxic peritoneal macrophages. 4. Hypoxia induced 
release of MCP-1 from alveolar, but not peritoneal macrophages or mast cells. 
These results demonstrate a direct link between alveolar macrophage 
activation by hypoxia and mast cell degranulation, and rule out possible roles of 
low tissue PO2 and of resident tissue macrophages in the early phase of the 
inflammation of alveolar hypoxia. The results add a key piece of evidence that 
confirms our hypothesis that the inflammation produced by alveolar hypoxia is 
triggered by an alveolar macrophage-borne mediator(s) carried by the circulation. 
The release by alveolar macrophages exposed to hypoxia of a mast cell 
secretagogue, MCP-1, provides evidence concerning the nature of a possible 
mediator of inflammation. 
 
Studies in the mesenteric microcirculation 
The objectives of the in vivo studies in the mesenteric microcirculation were 
two: first, since the mast cells and resident tissue macrophages used in the 
present experiments were collected from the peritoneum, it was important to 
determine whether the responses of the primary cell cultures to the various 
interventions were similar to those observed in vivo. Peritoneal mast cells and 
macrophages were selected because they can be harvested with minimal 
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manipulation, and therefore their responses are least affected by the isolation 
procedures. The second objective of the in vivo studies was to demonstrate 
whether the response of the mesenteric microcirculation to hypoxic alveolar 
macrophage supernatant is similar to that observed previously in the cremaster. 
A difference in the responses of these two vascular beds would argue against 
our hypothesis that the widespread inflammation of alveolar hypoxia in the intact 
animal is triggered by a mediator released into the circulation by activated 
alveolar macrophages.  
Topical application of supernatant of alveolar macrophages equilibrated with 
10% O2 produced essentially the same response in the mesentery as that 
observed previously in the cremaster microcirculation (Gonzalez et al., 2007b): 
mast cell degranulation, and increased leukocyte-endothelial adherence (Figure 
1A). 
An important new finding of these experiments was that supernatant of 
peritoneal macrophages exposed to a more severe level of hypoxia than alveolar 
macrophages did not initiate an inflammatory response in the mesentery (Figure 
1C). This observation is consistent with the failure of hypoxia to induce a 
respiratory burst in cultures of peritoneal macrophages (Table 1). These findings, 
together with the absence of in vivo cremaster inflammation during selective 
cremaster hypoxia in the presence of normal alveolar PO2 (Dix et al., 2003; Shah 
et al., 2003) indicate that resident tissue macrophages do not contribute to the 
initiation of the systemic inflammation of alveolar hypoxia. 
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In summary, the results show that the inflammatory response to supernatant of 
hypoxic alveolar macrophages has similar characteristics in the mesenteric and 
in the skeletal muscle microcirculations, and supports hypothesis that the 
widespread inflammation of alveolar hypoxia is the result of mast cell activation 
by an agent released by alveolar macrophages.  
 
Studies in the primary cell cultures 
Alveolar macrophages, but not peritoneal macrophages responded with a 
transitory release of H2O2 when exposed to hypoxia. The H2O2 release is a 
manifestation of the respiratory burst which occurs during macrophage activation 
(Ma et al., 2003) and is characterized by superoxide generation followed by 
dismutation to H2O2. In addition to an important role in inactivation of phagocyted 
pathogens, reactive O2 species generated during the respiratory burst are 
thought to play a role in intracellular signal transduction (Gwinn and Vallyathan, 
2006; Iles and Forman, 2002). In the present experiments, the amount of H2O2 
released by alveolar macrophages was largest at the lowest PO2. The correlation 
between the magnitude of the respiratory burst and the severity of hypoxia in the 
presence of maintained cell viability indicates that this is a biological response of 
alveolar macrophages to reduced PO2. On the other hand, peritoneal 
macrophages exposed to the same PO2 did not become activated. The dissimilar 
effects of hypoxia on activation of the two types of macrophages are paralleled 
by the different effects of their supernatants on mast cells: while supernatant of 
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hypoxic alveolar macrophages elicited degranulation of mast cells both in vivo 
(Figure 1A) and in vitro (Figure 4B), supernatant of hypoxic peritoneal 
macrophages exposed to much lower PO2 had none of these effects (Figure 1C 
and 4C). Thus, evidence obtained both in vivo and in vitro points to a specific 
effect of reduced PO2 on alveolar macrophages.  
The discrepancy between alveolar and peritoneal macrophages in the 
response to hypoxia is a manifestation of the different characteristics of these 
two cell types. While both originate from a common precursor in the bone 
marrow, alveolar macrophages in vivo are normally exposed to a higher PO2 than 
peritoneal macrophages. These different environments may in part determine 
their different metabolic patterns (Simon et al., 1977) and perhaps explain the 
dissimilar effects of hypoxia.  
The present experiments clearly demonstrate a link between activation of 
alveolar macrophages by hypoxia and mast cell degranulation: degranulation did 
not occur when mast cells were directly exposed to hypoxia, but was observed 
when the mast cells were immersed in supernatant of alveolar macrophages that 
had been equilibrated in hypoxia. This shows that hypoxic alveolar macrophages 
release an agent which produces mast cell degranulation. This agent is not 
released by normoxic alveolar macrophages or by hypoxic peritoneal 
macrophages which show no evidence of activation. Our earlier in vivo finding 
that selective cremaster hypoxia does not induce mast cell degranulation in rats 
with normal alveolar PO2 (Dix et al., 2003) agrees with these in vitro observations 
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and demonstrate that neither reduced local PO2 nor activation of resident tissue 
macrophages participate in the systemic inflammation of hypoxia. 
A key issue in this phenomenon is the nature of the mediator released by 
alveolar macrophages in response to hypoxia. There is evidence that alveolar 
hypoxia leads to pulmonary inflammation in rats (Madjdpour et al., 2003), and 
alveolar macrophages play an important role in this phenomenon. Hypoxia 
increases expression of TNF-α and MIP-1ß either in the lung or in isolated 
alveolar macrophages (Madjdpour et al., 2003; VanOtteren et al., 1995). In 
addition, hypoxia acts as a synergist in the interaction of several pathogens with 
alveolar macrophages (Agorreta et al., 2005; Leeper-Woodford and Detmer, 
1999; Vuichard et al., 2005). However, while these responses may influence the 
development of pulmonary and systemic inflammation later on in the course of 
hypoxia, it is unlikely that the phenomenon described in the present experiments 
is a consequence of changes in gene expression. Given the rapid onset of the 
response to hypoxia, and the fact that the targets are the mast cells, the putative 
mediator of systemic inflammation is likely to be a mast cell secretagogue stored 
in alveolar macrophages. To provide additional information on this subject, 
several possible candidates were screened. MCP-1 was observed to increase 
significantly in the supernatant of alveolar macrophages exposed to hypoxia in 
the time frame used in these studies. Peritoneal macrophages or mast cells did 
not release MCP-1 when exposed to even lower PO2. MCP-1, a chemokine of 
the CC family, fits the criteria for a putative mediator of hypoxia-induced 
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inflammation: MCP-1 induces chemotaxis of alveolar macrophages, mast cells, 
and human T-lymphocytes (de Boer et al., 2000). MCP-1 is released from 
alveolar macrophages in vitro in response to hypoxia and hypoxia/reoxygenation 
(McCourtie et al., 2008; Zhao et al., 2006), influences distal organ damage in 
hemorrhagic shock (Frink et al., 2007) and activates mast cells to elicit 
microvascular inflammation (Conti et al., 1995; Wan et al., 2003). Further studies 
are necessary to determine the mechanism underlying the release of MCP-1 by 
alveolar macrophages, the interaction of MCP-1 with mast cells, and whether 
other alveolar macrophage-borne agents participate in the activation of mast 
cells. Nevertheless, the demonstration of increased release of a mast cell 
secretagogue provides confirmation to our hypothesis that the systemic 
inflammation of hypoxia is initiated by an alveolar macrophage-borne mediator. 
The present results highlight the role of alveolar macrophages in initiating an 
inflammatory response in the systemic microcirculation. Although most known 
functions of these cells take place within the lung, mounting evidence indicates 
that alveolar macrophage activation leads to systemic inflammation and 
microvascular function impairment. For example, following activation by 
phagocytosis of particulate matter, cytokines released by alveolar macrophages 
act on the bone marrow to mobilize platelets and leukocytes which stimulate the 
release of acute phase proteins and lead to systemic inflammation (Ishii et al., 
2005; van Eeden et al., 2001). The phenomenon described in the present study 
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represents an example of systemic effects initiated by activation of alveolar 
macrophages by another type of stimulus, in this case, reduction of alveolar PO2. 
Several conditions featuring alveolar hypoxia are accompanied by systemic 
effects, and inflammation has been implicated as a causative or contributory 
factor in these systemic effects. These include the cachexia and muscle wasting 
(Agusti and Soriano, 2008; Wust and Degens, 2007) and the cardiovascular 
abnormalities (Eickhoff et al., 2008) of COPD, the suboptimal erythropoiesis of 
pulmonary fibrosis (Tsantes et al., 2003b) and the cardiovascular complications 
of sleep apnea (Jelic et al., 2008; Morgan, 2007). Conditions in which hypoxia 
develops rapidly are also accompanied by a systemic inflammatory component. 
For instance, pneumonia is accompanied by systemic inflammation, and elevated 
circulating inflammatory markers are predictors of subsequent mortality 
(Fernandez-Serrano et al., 2003; Yende et al., 2008). While these markers may 
in part reflect the response to bacterial infection, it is conceivable that the hypoxic 
environment in areas of lung consolidation may lead to activation of alveolar 
macrophages which contribute to the systemic inflammation.  
Acute altitude illnesses represent another example of systemic inflammatory 
response to alveolar hypoxia. Rapid ascent to high altitude is increasingly 
frequent and may result in acute mountain sickness or high altitude cerebral 
edema (Basnyat and Murdoch, 2003). While the role of inflammation in these 
cases is still unclear, the presence of elevated levels of circulating and tissue 
inflammatory markers (Beidleman et al., 2006; Hartmann et al., 2000; Klausen et 
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al., 1997), and the effectiveness of dexamethasone, an anti-inflammatory steroid, 
in the treatment of acute mountain sickness and high altitude cerebral edema 
(Basnyat and Murdoch, 2003; Wright, 2006) suggest the contribution of an 
inflammatory component. Whether activation of alveolar macrophages plays a 
role in the pathogenesis of these and other conditions associated with alveolar 
hypoxia should be the subject of further research. 
It is important to keep in mind that reduction of alveolar PO2 in an intact 
organism is a complex stimulus which sets in motion responses with different 
time courses; accordingly, a number of mechanisms may participate at different 
moments in the course of hypoxia. For example, increased leukocyte-endothelial 
adhesive interactions in response to hypoxia have been demonstrated in isolated 
human umbilical veins, in which the phenomenon described here clearly does not 
occur (Michiels et al., 2000). However, the time course of the in vitro responses 
(hours vs minutes) is quite different from that described in the present 
experiments, suggesting that the underlying mechanisms are different from those 
described here. 
In summary, the present study provides key evidence in support of our 
hypothesis that the inflammation of alveolar hypoxia is initiated by the release of 
a mediator from alveolar macrophages. This evidence includes the identification 
of a possible mediator of this phenomenon, a mast cell secretagogue produced 
by alveolar macrophages. Further research is necessary to determine whether 
other agents participate, and to develop tools to antagonize the mediator’s 
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effects. This should help understand the possible contribution of this 
phenomenon to the pathogenesis of illnesses associated with reduced alveolar 





Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) 
released from alveolar macrophages mediates the 
systemic inflammation of acute alveolar hypoxia  
 4.1  Introduction 
   The previous data from our lab suggest that the systemic inflammation 
elicited by alveolar hypoxia is not triggered by the reduction of peripheral tissue 
PO2, but rather by a mediator(s) released from alveolar macrophages and 
transported by the circulation (Chao et al., 2009a; Chao et al., 2009b; Gonzalez 
et al., 2007a). The mediator activates local tissue mast cells which release 
inflammatory agents, including activation of the RAS (Gonzalez et al., 2007b), to 
initiate the systemic inflammation. Mast cells play a key event since the mast cell 
stabilizer cromolyn attenuates all of the markers of inflammation induced by 
alveolar hypoxia (Shah et al., 2003; Steiner et al., 2003). Alveolar macrophages 
are the origin of the mediator, which is supported by several lines of evidence: 1) 
Depletion of alveolar macrophages attenuates the systemic inflammatory 
response induced by alveolar hypoxia (Gonzalez et al., 2007a); 2) Plasma 
obtained from intact hypoxic rats, but not from alveolar macrophage-depleted 
hypoxic rats, produce an inflammatory response in normoxic cremaster 
(Gonzalez et al., 2007a). The effect of hypoxic rat plasma is not due to 
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inflammatory mediators released into plasma by activated mast cells or adherent 
leukocytes of the donor rat; furthermore, the agent(s) responsible for the 
inflammation is not generated by blood cells (Orth et al., 2005). 3) Topical 
application of supernatant from hypoxic alveolar macrophages produces mast 
cells degranulation and increased leukocyte-endothelial adherence in normoxic 
cremaster and mesentery post-capillary venules (Chao et al., 2009a; Gonzalez et 
al., 2007a). 5)  Primary alveolar macrophage cultures undergo a respiratory 
burst within 15 min of reduction of PO2; in contrast, neither peritoneal mast cells 
nor peritoneal macrophages primary cultures are stimulated by hypoxia within 
this time frame (Chao et al., 2009a). However mast cells are rapidly activated 
when immersed in supernatant of hypoxic alveolar macrophages, but not of 
hypoxic peritoneal macrophages (Chao et al., 2009a). 
The nature of the mediator(s) released by alveolar macrophages to trigger the 
inflammation is not clear. Alveolar macrophages are a rich source of oxidants, 
cytokines, chemokines, growth factors, and arachidonic acid metabolites, which 
can be secreted in response to several stimuli, including hypoxia and 
ischemia/reperfusion (Chao et al., 2009a; Naidu et al., 2002; VanOtteren et al., 
1995). Chemokines are primary products of activated alveolar macrophages 
(Ben-Baruch et al., 1995). The chemokine super family has been subdivided into 
four sub-families, which differ with respect to the number and arrangement of the 
conserved cysteine residues at the N terminus of the primary amino acid 
sequence (Murphy, 1996). Monocyte chemoattractant protein-1 (MCP-1/CCL2), 
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the prototype of the CC-chemokine subfamily, is an attractive candidate for a 
mediator of the systemic inflammation of alveolar hypoxia: MCP-1 is endowed 
with chemotactic and activating properties for macrophages (Fuentes et al., 
1995), CD4+/CD8+ T lymphocytes (Carr et al., 1994) and mast cells, and is 
critically involved in the regulation of inflammatory processes. MCP-1 induces 
mast cells degranulation and leukocyte endothelial adherence in the rat 
cremaster microcirculation (Wan et al., 2003). A possible role of MCP-1 as a 
putative mediator of the systemic inflammation of alveolar hypoxia is suggested 
by our previous observation that primary cultures of alveolar macrophages, but 
not of peritoneal macrophages or mast cells, release MCP-1 within minutes of a 
reduction in PO2 (Chao et al., 2009a). Release of MCP-1 by alveolar 
macrophages has also been observed after hypoxia-reoxygenation 
(Krishnadasan et al., 2003; McCourtie et al., 2008; Penner, 1988), which 
influences distal organ damage in hemorrhagic shock (Frink et al., 2007) and 
activates mast cells to elicit microvascular inflammation (Conti et al., 1995; Wan 
et al., 2003). 
The objective of the present experiments was to provide definitive evidence 
concerning a possible role of MCP-1 as the circulating mediator that initiates the 
systemic inflammation of alveolar hypoxia. We reasoned that if MCP-1 does play 
this role, the plasma concentration of MCP-1 should increase in animals exposed 
to hypoxia, the time course and magnitude of this increase should be sufficient to 
elicit systemic effects, and these effects should be clearly ascribed to activation 
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of mast cells by MCP-1 released from alveolar macrophages. The results 
obtained show that MCP-1 is indeed a key initiator of the systemic inflammation 
of alveolar hypoxia.  
 
4.2   Methods 
The general methods and techniques utilized are described in detail in chapter 
2.  
 
4.2.1   Filtration experiments 
  Samples of normoxic plasma obtained from intact rats and from normoxic, 
alveolar macrophage-depleted rats, and samples of normoxic alveolar 
macrophages supernatant were filtered using Amicon Ultra filter device (30KDa, 
50KDa or 100KDa) and centrifuged at 14000×g for 30 minutes. Usually, two 0.5 
aliquots from each sample were filtered. The filtrates were collected and diluted 
to original volume with serum-free DMEM. The retained fractions were collected 
by centrifuging the filter upside down in a clean centrifuge tube at 1000×g for 2 
minutes, then diluted to original volume with serum-free DMEM. In every case, 
0.4×106 isolated mast cells were suspended in 0.4ml aliquots of filtrate or of the 
retained fraction. Four μl of 3000ng/ml MCP-1 (dissolved in serum free DMEM) 
was added to each culture to yield final concentration of 30 ng/ml. The cells were 
incubated for 20 minutes and then centrifuge at 3000 rpm for 2 minutes. The 
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cells were resuspended in 40μl of ruthenium red (50 μg/ml) to yield cell 
concentration of 107cell/ml. The percentage of degranulated mast cells was 
checked with cell smear using Nikon TE2000-S microscope. Photographs were 
obtained from 5 different areas of the slide, containing approximately 20 cells 
each area. 
 
4.3   Results 
4.3.1 Hypoxia-induced release of MCP-1 from isolated alveolar 
macrophages 
Primary alveolar macrophage cultures were equilibrated with gas mixtures 
selected to reproduce the PO2 to which alveolar macrophages may be exposed 
in vivo under various conditions. A gas mixture of 15% O2 provides an 
environment similar to that of the normoxic alveolar gas, i.e. a PO2 of 
approximately 100 Torr. The 10% and 5% O2 gas mixtures provide alveolar PO2 
values observed in conditions of moderate hypoxia (PO2 ~ 70 mm Hg) and 
severe hypoxia (PO2 ~ 35 mm Hg). Equilibration with gas mixtures nominally 
containing 0% O2 seldom results in total absence of O2 in the solution; with the 
equilibration method used in these experiments PO2 of the solution is 
approximately 5 mm Hg in these conditions (Chao et al., 2009a). While this is far 
below levels to which alveolar macrophages may be exposed in vivo, these 
values approximate the systemic microvascular PO2 values that are observed in 
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rats breathing 10% O2 (Dix et al., 2003; Shah et al., 2003) and to which mast 
cells and systemic tissue macrophages may be exposed during hypoxia.  
The basal release of MCP-1 into the supernatant of primary cultures of alveolar 
macrophages equilibrated with 15% O2 was 200 ±32 pg/10
6 cells (N = number of 
cell cultures = 5). In contrast, MCP-1 released by alveolar macrophages during 
30 minutes of equilibration with the hypoxic gas mixtures was nearly 20-fold 
greater (Table 2). However, there was no correlation between the magnitude of 
MCP-1 released and the oxygen tension of the equilibrating gas mixtures in the 
range of 0-10% O2. Viability of alveolar macrophages, assessed by Trypan Blue 
exclusion at the end of the experiments ranged from 99.4±0.1% with 15% O2 to 
99.6±0.1% with 10% O2. 
 
Table 2 Hypoxia-induced release of MCP-1 from primary AMØ cultures 
Nominal % O2 15% 10% 5% 0% 
N 5 5 5 5 
Supernatant concentration of 
MCP-1 (pg/106 cell) 
200±32 4051±591* 3757±909* 4119±354* 
Values are mean ± SE of 5 primary cultures of AMØ exposed to each of the gas mixtures 
N = number of primary cultures exposed to each gas mixture 
* P<0.01 vs. 15% O2 group 
 
4.3.2   CCR2b receptor antagonist prevents degranulation of isolated mast 
cells immersed in supernatant of hypoxic alveolar macrophages  
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Peritoneal mast cells were immersed in supernatant of alveolar macrophages 
exposed to normoxic (15% O2) hypoxic alveolar macrophages (5% O2) gas 
mixtures (Table 3). As expected (Chao et al., 2009a), mast cells immersed in 
normoxic alveolar macrophage supernatant did not degranulate, while hypoxic 
alveolar macrophage supernatant induced significant mast cell degranulation. On 
the other hand, peritoneal mast cells pretreated with the MCP-1 receptor 
antagonist RS-102895(10μM) showed no degranulation when immersed in 
supernatant of hypoxic alveolar macrophages.  Pretreatment with RS-102895 
did not affect C48/80-induced mast cells degranulation (Table 2). While RS-
102895 blocks MCP-1 effects by binding to the specific CCR2b receptor 
(Futagami et al., 2008), C48/80, a basic mast cells secretagogue, induces mast 
cell degranulation via a receptor-bypassing action which includes activation of 
the Gi/o class of G proteins (Metcalfe et al., 1997). 
 
Table 3 The MCP-1 receptor antagonist, RS-102895, prevents degranulation of mast cells 




Supernatant of AMØ 
exposed to 15% O2 
Supernatant of AMØ 
exposed to 5% O2 
Supernatant of AMØ 
exposed to 5% O2 + 
C48/80 
Untreated 3.6±0.5 74.7±0.3 87.5±1.7§ 
RS-102895 - 14.2±1.3* 84.5±4.3# 
 
  Mast cells from the same culture (0.4×106 cells) were immersed in supernatant of AMØ 
exposed to either 15 or 5% O2. The supernatants contained RS-102895, the mast cell 
secretagogue c48/80, or both. Untreated AMØ supernatant contained neither of these. Mast cell 
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degranulation was assessed 20 min after immersion. N= number of cell cultures studied=3. * 
P<0.01 vs. corresponding untreated group; § P<0.01 vs. corresponding C48/80 group. 
 
4.3.3   Plasma MCP-1 levels of intact and of alveolar macrophage-depleted 
conscious rats breathing 10% O2 
  Hypoxia induced a significant increase of MCP-1 in plasma of rats with normal 
number of alveolar macrophages (Figure 6). The number of alveolar 
macrophages recovered by BAL in these rats, treated with PBS liposomes, was 
7.74±0.34×106 cells/rat (N=5). MCP-1 was already increased at 5 minutes of 
hypoxia, and remained elevated at similar levels for the remainder of the hypoxic 
exposure.  On the other hand, in the rats in which alveolar macrophages had 
been depleted with injection of clodronate-containing liposomes (number of 
alveolar macrophages recovered by BAL = 0.32±0.05×106 /rat; N=5) plasma 
MCP-1 concentration remained unchanged from normoxic values for the first 30 
min, and increased significantly only after 60 min of hypoxia, at which time it 






























Plasma MCP-1 concentration in conscious AMØ- depleted (solid circles) and intact (open 
circles) rats before and during 1 h of breathing 10 % O2. AMØ were depleted by tracheal 
instillation of clodronate-containing liposomes 4 d before the experiment. Intact rats received 
PBS-containing liposomes. Bars are mean ± SE, N= 5 rats per group in each data point: *** = 
P<0.01 vs. corresponding normoxic control: §= P <0.01 vs. corresponding value in intact rats.  
 
Peritoneal mast cells (0.4×106 cells) obtained from normoxic rats were 
immersed in the plasma samples (0.4 ml) obtained from the conscious rats 
breathing 10% O2.  Essentially no degranulation was observed when peritoneal 
mast cells were immersed into the plasma samples obtained during the normoxic 
control period of either intact or alveolar macrophage-depleted rats (Figure 7). 
Mast cell degranulation increased significantly when the cells were immersed in 
plasma obtained when the intact rats were breathing 10% O2; the percentage of 
degranulated mast cells was essentially the same in samples withdrawn at 




mast cells were immersed in plasma from the hypoxic, alveolar macrophage-
depleted rats. This was the case even when mast cells were immersed in plasma 






















AM   -depleted rats
Intact rats
*** *** ***
Nx plasma                                  Hx plasma  
Figure 7 
Percent of degranulated mast cells after immersion in rat plasma. Peritoneal mast cells (0.4× 
106 cells) from normoxic intact rats were immersed in 0.4 ml of plasma obtained from the rats 
depicted in Figure 6 at the times indicated in the horizontal axis. Black bars: AMØ-depleted rats; 
gray bars: intact rats. *** = P<0.01 vs. corresponding normoxic control. §= P<0.01 vs. 
corresponding value in intact rats 
 





The data of the previous section show that, in general, degranulation occurred 
when mast cells were immersed in plasma form hypoxic intact rats, which had 
high MCP-1 levels, and did not degranulate when immersed in plasma of hypoxic 
alveolar macrophage-depleted rats, which showed lower levels of MCP-1.  To 
further explore the dependence of mast cell degranulation on MCP-1 
concentration, mast cells were exposed to increased concentrations of MCP-1 
dissolved in plasma obtained from normoxic rats, in supernatant of normoxic 
alveolar macrophages, and in normoxic, serum-free DMEM. In all cases 0.4×106 
mast cells were immersed in 0.4 ml of solution. Mast cell degranulation was 
observed 20 min after immersion.  Figure 8 plots percent of degranulated mast 
cells as a function of MCP-1 added to the solution. The data obtained when mast 
cells were immersed in the plasma obtained during 10% O2 breathing –from both 
intact and alveolar macrophage-depleted rats (Figure 6) - are included for 
comparison. For these samples, the percent of mast cell degranulation observed 
was plotted as a function of the plasma MCP-1 concentration determined by 
ELISA.  
Mast cells immersed in normoxic rat plasma obtained or in normoxic alveolar 
macrophage supernatant showed essentially the same MCP-1 concentration-
dependent mast cell degranulation. This relationship also fits the data obtained in 
mast cells immersed in plasma withdrawn from intact rats breathing 10% O2 
(Figure 8, solid red diamonds). Mast cells immersed in the plasma samples 
obtained when the alveolar macrophage-depleted rats were breathing 10% O2 
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showed no increase in degranulation (Figure 8, open red diamonds). This was 
the case even for the sample obtained at 60 min of hypoxia which showed MCP-
1 concentration of 8 ±1.3 ng/ml. This concentration would produce degranulation 
of approximately 40% of the mast cells immersed in normoxic plasma or alveolar 
macrophage supernatant (Figure 8). This suggests that alveolar macrophages 
are necessary for plasma to elicit MCP-1-mediated mast cell degranulation.   
In marked contrast to normoxic plasma and normoxic alveolar macrophage 
supernatant, MCP-1 added to normoxic culture medium failed to increase mast 
cell degranulation, even at the highest MCP-1 concentration. A possible 
explanation for this is that a substance(s) present in normoxic plasma and in the 
supernatant of normoxic alveolar macrophages, but absent in plasma of alveolar 
macrophage-depleted rats, is necessary for MCP-1 to induce degranulation of 

































Peritoneal mast cells obtained from normoxic intact rats (0.4×106 cells) were immersed in 0.4 
ml of solutions containing increasing concentrations of MCP-1. Mast cells were immersed in 
normoxic AMØ supernatant (green), in normoxic plasma (blue) and in serum-free DMEM culture 
medium (black). Data are mean ± SE of 3 experiments per group in each data point. The red 
diamonds represent the data obtained immersing mast cells in the plasma drawn from the AMØ-
depleted rats (open diamonds) and the intact rats (solid diamonds) breathing 10% O2 depicted in 
Figure 7. 
 
 4.3.5   Filtration of plasma and alveolar macrophage supernatant 
To obtain preliminary evidence of a putative co-factor of MCP-1, normoxic 
plasma from intact and from alveolar macrophage-depleted rats, as well as 
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supernatant of normoxic alveolar macrophages, were filtered through pores of 
different sizes. Aliquots of MCP-1 were added to the filtrate as well as the 
retained fractions to obtain a concentration ~ 30 ng/ml. This concentration 
produces degranulation of ~ 75% of mast cells immersed in plasma of intact rats 
or in alveolar macrophage supernatant (Figure 7). Peritoneal mast cells obtained 
from normoxic intact rats were then added to the fractions containing MCP-1, and 
mast cell degranulation was determined 20 min later. The results obtained using 
either plasma from intact rats or alveolar macrophage supernatant were 
essentially (Table 4). On the other hand, no degranulation occurred when mast 
cells were added to any of the filtrate or of the retained fraction of plasma 
obtained from alveolar macrophage-depleted rats.  
MCP-1 induced mast cell degranulation in only two cases: in the fraction of 
plasma or alveolar macrophage supernatant retained by the 30 KDa filter; and in 
the filtrate of the 100 KDa filter. No mast cell degranulation was observed in 
either fraction when the 50KDa filter was used. The best explanation for these 
results is that the MCP-1 cofactor is composed of two elements: one with a size 
between 30 and 50 KDa, and another with a size larger than 50 and smaller than 
100 KDa. Both elements would be together in the retained fraction of the 30 KDa 
filter, as well as in the filtrate of the 100 KDa filter. Mast cell degranulation in 
either fraction of the 50 KDa filter would not occur because the co-factor 





Table 4  Effect of different filtered fractions of normoxic plasma and AMØ supernatant on 
degranulation of immersed mast cells 
Pore size Fraction 
% of degranulated mast cells 
Plasma of intact rats 
(n=3) 
Supernatant of 
normoxic AMØ (n=3) 
Plasma of AMØ-
depleted rats (n=3) 
30KDa 
retained 76.7±1.3* 72.6±1.6* 5.4±1.1 
filtrate 5.2±1.3 4.8±1.5 6.2±1.3 
50KDa 
retained 5.4±2.6 4.3±0.9 6.0±1.4 
filtrate 5.1±0.4 5.6±1.3 6.7±0.2 
100KDa 
retained 3.7±1.5* 5.4±1.0* 6.8±0.8 
filtrate 75.0±3.4 75.2±1.2 6.1±1.0 
MCP-1 (30 ng/ml) and mast cells (0.4×106 cells in a final volume of 0.4 ml) were added to the 
retained fraction or the filtrate. Mast cell degranulation was assessed 20 min after immersion. N = 
number of primary cultures. * P<0.01 vs. corresponding filtrate 
 
In addition to providing evidence of the existence of this co-factor, the data 
also suggest that the co-factor originates in alveolar macrophages: similar results 
were obtained immersing mast cells into plasma or in alveolar macrophage 
supernatant suggesting that this substance is released by alveolar macrophages 
into the plasma; this is supported by the finding that there is no evidence of the 
presence of a co-factor in plasma of alveolar macrophage-depleted rats. These 
data are consistent with the observation that mast cells did not degranulate when 
immersed in the plasma sample obtained after 60 min of hypoxia in the alveolar 
macrophage-depleted rats, which showed a significant increase in MCP-1 




4.3.6  CCR2b receptor antagonist prevents the inflammatory response to 
alveolar hypoxia in the mesentery of intact rats    
These experiments were carried out to explore the possible role of MCP-1 in 
the systemic inflammation of alveolar hypoxia in anesthetized intact rats. Figure 9 
shows representative microphotographs of a mesenteric post-capillary venule of 
an intact rat obtained before (left) and at 30 min of 10% O2 breathing (center). 
The microphotograph at the right shows the effect of 30 min of alveolar hypoxia 
in a rat pretreated with RS-102895 (10 μM applied topically). Hypoxia in the 
untreated rats resulted in the expected inflammatory response: increases in mast 
cells degranulation index and in leukocyte-endothelial adherence. These effects 




Representative microphotographs of post capillary mesenteric venules of intact rats The large 
black dots are used to align the optical Doppler velocimeter used to measure red cell velocity, 
and occasionally are moved from the vessel center to obtain a better view of the leukocyte-
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endothelial interface for photographs. The left and center photographs were taken before and at 
30 min of breathing 10% O2, respectively. The red arrows point to mast cell and the green arrows 
point to adherent leukocytes. Hypoxia induces mast cell degranulation, as shown by the uptake of 
ruthenium red, and increased adherence of leukocytes to the endothelium. The photograph on 
the right shows a venule of an intact rat pretreated with the CCR2b receptor antagonist RS-
102895 (10 μM applied topically). The photograph was obtained at 30 min of 10% O2 breathing. 
In contrast with the photograph in the center, pretreatment with RS-120895 prevents mast cell 
degranulation and leukocyte-endothelial adherence of alveolar hypoxia. The numbers below the 
photographs represent mean ± SE of 5 rats in each group. LEA: leukocyte-endothelial adherence 
as determined by leukocytes /100 μm. MCDI: Mast cell degranulation intensity, arbitrary units. 
 
4.3.7   Effects of topical MCP-1 on the microcirculation of intact and 
alveolar macrophage-depleted rats 
The data of Figure 8 suggest that MCP-1 participates in the mesenteric mast 
cells degranulation and increased leukocyte-endothelial adherence that occur at 
onset of alveolar hypoxia. Further evidence on this was obtained using an 
alternative approach, namely determining the effect of administration of MCP-1 to 
normoxic rats with normal alveolar macrophage count.  
Topical application of MCP-1 (30 ng /ml dissolved in serum-free DMEM) to the 
mesentery of intact, normoxic rats mimicked the response to alveolar hypoxia 
(compare left and center panels of Figure 9). Pretreatment of the mesentery with 





Mesenteric post capillary venule immediately before (left) and 30 min after topical application 
of MCP-1 (30 ng/ml dissolved in serum-free DMEM). Red arrows: mast cells, green arrows: 
adherent leukocytes. Right panel: mesenteric venule 30 min after application of MCP-1 in a rat 
topically pretreated with RS-102895 (10 μM), a CCR2b antagonist. Data are mean ± SE of 5 rats 
per group. * P<0.01 vs. corresponding control 
 
In contrast, the effect MCP-1 on the mesentery of alveolar macrophage-
depleted rats depended on the vehicle into which MCP-1 was dissolved. MCP-1, 
30 ng/ml dissolved in serum-free DMEM, had no effect on the mesentery of 
alveolar macrophage-depleted rats (Figure 11, left). On the other hand, topical 
application of equal amounts of MCP-1 dissolved in plasma obtained from 
normoxic rats with normal alveolar macrophage count produced an inflammatory 
response (Figure 11, right). The effects of MCP-1 here were similar to those seen 






Left: Post capillary mesenteric venule of an AMØ-depleted rat 30 min after topical application 
of 30 ng/ml of MCP-1 dissolved in serum-free DMEM. Right: Post capillary mesenteric venule of 
an AMØ-depleted rat 30 min after topical application of 30 ng/ml of MCP-1 dissolved in plasma 
from intact rats. Data are mean ± SE of 5 rats in each group. * P<0.01 vs. corresponding control  
 
4.4  Discussion 
  The findings of the present experiments demonstrate that MCP-1 plays a 
central role in the initiation of the systemic inflammatory response to alveolar 
hypoxia. The results also show that a co-factor, normally present in normoxic 
plasma and originated in alveolar macrophages, is necessary for the stimulatory 
effect of MCP-1 on mast cells.  
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Our previous work has provided compelling evidence that the systemic 
inflammation of hypoxia is not initiated by the reduced tissue PO2, but rather by a 
mediator released from alveolar macrophages and transported by the circulation 
(Chao et al., 2009a; Dix et al., 2003; Gonzalez et al., 2007a; Gonzalez et al., 
2007b; Orth et al., 2005; Shah et al., 2003). A role for alveolar macrophage-
borne MCP-1 as the putative mediator was suggested by the previous finding 
that primary cultures of alveolar macrophages, but not of peritoneal mast cells or 
peritoneal macrophages, release MCP-1 within 30 min of exposure to hypoxia 
(Chao et al., 2009a). Of 12 different chemokines and cytokines investigated, 
MCP-1 was the only mast cell secretagogue released by alveolar macrophages 
within a time frame compatible with a role as a trigger of the inflammation. 
Hypoxia-induced release by alveolar macrophages of a mast cell secretagogue 
such as MCP-1 is consistent with the observation that cultures of hypoxic 
alveolar macrophages, but not of hypoxic peritoneal macrophages, elicited 
degranulation of immersed mast cells and induced inflammation in tissues of 
normoxic animals (Chao et al., 2009a; Chao et al., 2009b; Gonzalez et al., 
2007a). While these data provide evidence of the participation of MCP-1 in the 
inflammatory process, several criteria must be met to demonstrate that MCP-1 is 
the alveolar macrophage-borne circulating agent that initiates the systemic 
inflammatory cascade: First, reduction of alveolar PO2 in intact animals must 
result in an increase in plasma MCP-1 concentration, and this increase must 
follow a pattern consistent with the time course of the inflammatory response. 
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Second, alveolar macrophages must be identified as the source of the elevated 
plasma MCP-1 levels in intact animals. Third, the plasma concentration of MCP-1 
observed during hypoxia must be sufficient to elicit activation of mast cells, the 
target of the putative circulating mediator. Finally, evidence must be provided 
showing that MCP-1 is directly involved in the systemic inflammatory response to 
alveolar hypoxia in intact animals.  The data presented here show that all these 
criteria were met to identify MCP-1 as the agent that initiates the systemic 
inflammation of hypoxia. In addition, the results indicate that a co-factor present 
in normoxic biological fluids is necessary for MCP-1 to activate mast cells. The 
evidence supporting a role for MCP-1 as the key initiator of the inflammation will 
be discussed first, followed by discussion of the data that point to the existence 
of a co-factor for MCP-1.  
 
4.4.1 Alveolar macrophage-borne MCP-1 initiates the systemic 
inflammation of alveolar hypoxia 
    Breathing 10% O2 elicited a rapid and sustained increase in plasma MCP-
concentration in intact, conscious rats (Figure 6).  Within 5 minutes, MCP-1 had 
reached the levels that were maintained for 1 h of hypoxia. This rapid increase 
matches the time course of the mast cell degranulation and leukocyte-endothelial 
adherence observed in the mesenteric and cremaster microcirculations of rats 




The major source of the initial increase in plasma MCP-1 is evidently alveolar 
macrophages: First, reduction of PO2 does induce a rapid release of MCP-1 from 
primary cultures of alveolar macrophages (Table 2). The effectiveness of alveolar 
macrophage-borne MCP-1 in inducing mast cell degranulation is supported by 
the inhibitory effect of RS-102985 on degranulation of mast cells immersed in 
hypoxic alveolar macrophage supernatant (Table 3). Second, depletion of 
alveolar macrophages by administration of clodronate liposomes prevented the 
increase in plasma MCP-1 observed during the first 30 min of hypoxia in 
conscious rats. At 60 min of hypoxia, plasma MCP-1 in the alveolar macrophage-
depleted rats had increased to less than 50% of the value observed in the 
corresponding sample in the intact animals (Figure 6). It is not likely that the 
small number of alveolar macrophages remaining after 4 days of clodronate 
liposome treatment -less than 5% of the number recovered by BAL from the rats 
treated with PBS liposomes- is responsible for this increase. Besides the 
disproportionate levels of plasma MCP-1 in relation to the number of alveolar 
macrophages, it would be expected that MCP-1 released from these remaining 
alveolar macrophages would follow a time course similar to that observed in the 
control rats. Cells other than alveolar macrophages are probably the main 
contributors to the late increase in plasma MCP-1 in this case (Sharma et al., 
2007). Whether the stimulus for the delayed release of MCP-1 is the reduced 
tissue PO2 or some other factor associated with hypoxia in the intact animal is 
not known. Nevertheless, while MCP-1 from these alternative sources may 
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contribute to the systemic inflammation at later times, the time course indicates 
that it does not play a role in the rapid onset of the inflammation. Accordingly, 
these results indicate that alveolar macrophages are the predominant source of 
the early increase in plasma MCP-1during hypoxia.   
     A second criterion that must be met by the putative circulating mediator 
of the inflammation is that its plasma concentration during hypoxia must be 
sufficient to activate mast cells. Immersion of mast cells in the plasma samples 
drawn from the intact conscious rats breathing 10% O2, in which an elevated 
MCP-1 level was documented (Figure 6), produced substantial degranulation 
(Figure 7). No degranulation was observed when mast cells were immersed in 
normoxic plasma of intact or of alveolar macrophage-depleted rats, or in the 
plasma of the hypoxic, alveolar macrophage-depleted rats (Figure 7). Addition of 
MCP-1 to normoxic plasma or normoxic alveolar macrophage supernatant 
produced concentration-dependent degranulation of immersed mast cells (Figure 
8). The percent of degranulated mast cells immersed in the plasma samples 
drawn from the intact rats breathing 10% O2 (Figure 7) was close to  that seen 
when mast cells were immersed in normoxic plasma or normoxic alveolar 
macrophage supernatant with similar MCP-1 concentrations (Figure 8). These 
results indicate that the plasma MCP-1 level reached by the hypoxic rats with 
normal alveolar macrophage count is sufficient to induce mast cell degranulation, 
suggest that mast cell degranulation occurred as a result of the elevated MCP-1 
concentration, and was not the result of other factors associated with hypoxia. 
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The participation of MCP-1 in the inflammation induced by alveolar hypoxia in 
intact animals was investigated using complementary approaches. On one hand, 
pretreatment of the mesentery with RS-102985 prevented the rapid 
degranulation of perivascular mast cells and the increased leukocyte-endothelial 
adherence to mesenteric venules that is observed in the intact rats breathing 
10% O2 (Figure 9). RS-102895 is a selective antagonist of CCR2b, the putative 
MCP-1 receptor expressed in mast cells (Ko et al., 2006) and in endothelial cell 
membranes (Schols et al., 1994). Secondly, topical application of MCP-1 onto 
the mesenteric microcirculation of normoxic intact rats reproduced the 
inflammatory response to systemic hypoxia (Figure 10).  This response was 
prevented by administration of RS-102985 in the same dose used to block the 
effect of alveolar hypoxia (Figure 9). Both RS-102985 and MCP-1 were 
administered topically. This avoided possible systemic responses to these agents 
which could influence the results. The MCP-1 concentration of the solutions 
applied approximated the plasma MCP-1 concentration observed in intact rats 
during hypoxia. 
In summary, a combination of in vivo and in vitro data show that alveolar 
macrophages release MCP-1 under hypoxia, and that this release leads to an 
increase in plasma concentration of MCP-1 with a time course compatible with 
that of the systemic inflammation. Furthermore, the plasma MCP-1 level attained 
at the onset of hypoxia is sufficient to induce mast cell degranulation, the first 
step in the systemic inflammatory cascade. Finally, participation of MCP-1 in the 
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systemic inflammation of alveolar hypoxia is supported by the attenuation of the 
inflammation by MCP-1 receptor blockade in rats breathing 10% O2. This was 
complemented by the observation that administration of MCP-1 to normoxic rats 
replicates the mesenteric inflammation produced by hypoxia.  
 
4.4.2   Evidence supporting the existence of a MCP-1 co-factor 
While these results provide substantial evidence supporting MCP-1 as the 
alveolar macrophage-borne circulating mediator which initiates the inflammation 
of alveolar hypoxia, it is also apparent that MCP-1 requires a co-factor to activate 
mast cells at concentrations observed under physiologically relevant conditions.  
This was initially suggested by the observation that MCP-1 did not produce 
degranulation of mast cells immersed in normoxic cell culture medium, even at 
concentrations that were effective in plasma or in alveolar macrophage 
supernatant (Figure 8). This finding is consistent with earlier reports of a lack of 
effect of MCP-1 on degranulation of in vitro mast cell cultures (Alam et al., 1992; 
Fureder et al., 1995). In fact, release of histamine by rat peritoneal mast cell 
cultures was observed only when MCP-1 was administered in concentrations 10 
to 20-fold greater than those seen in plasma of hypoxic rats; lower 
concentrations had no effect (Conti et al., 1995). These results are in marked 
contrast with the documented effectiveness of MCP-1 in activating mast cells in 
vivo (Wan et al., 2003). 
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The filtration experiments provided more direct evidence for the existence of 
such a co-factor in normoxic plasma and alveolar macrophage supernatant. Mast 
cell degranulation induced by MCP-1 was interpreted as an indicator of the 
presence of the co-factor in a given fluid fraction. The results, which were 
essentially the same in plasma from intact normoxic rats and in normoxic alveolar 
macrophage supernatant, suggest that the co-factor is composed of at least two 
fractions: one with a molecular weight between 30 and 50 kDa and the other with 
a molecular weight between 50 and 100 kDa (Table 4).  
Several lines of evidence suggest that the co-factor is constitutively secreted 
by alveolar macrophages and is normally present in plasma and extracellular 
fluid. First, alveolar macrophages are necessary for MCP-1 to induce mast cell 
degranulation: mast cells immersed in plasma obtained from alveolar 
macrophage-depleted rats after 60 min of 10% O2 breathing did not undergo 
degranulation. This was in spite of the fact that this sample exhibited a MCP-1 
concentration that produces degranulation of 40-50% of mast cells immersed in 
plasma from intact rats or in alveolar macrophage supernatant (Figure 8). These 
results are consistent with the results of the filtration experiments, which showed 
no MCP-1-induced mast cell degranulation in any of the fractions of plasma from 
alveolar macrophage-depleted rats. Further support for the idea of an alveolar 
macrophage-borne co-factor for MCP-1 was provided by the results depicted in 
Figures 10 and 11. Topical MCP-1 dissolved in serum-free DMEM replicated the 
response to hypoxia in the mesentery of intact, normoxic rats (Figure 10), while it 
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had no effect in the alveolar macrophage-depleted rats (Figure 11). On the other 
hand, MCP-1 dissolved in plasma of rats with normal alveolar macrophage count 
did produce an inflammatory response in the alveolar macrophage–depleted rats. 
These results imply that absence of the co-factor in the mesenteric environment 
of the alveolar macrophage-depleted rats prevented the mast cell degranulation 
when MCP-1 was dissolved in DMEM; however, when the co-factor was provided 
using plasma of intact rats as a vehicle, MCP-1 did elicit mast cell degranulation 
in the mesentery of alveolar macrophage-depleted rats.  
These results provide persuasive evidence of an alveolar macrophage-borne 
co-factor of MCP-1; its nature, however, remains unknown. Since this substance 
appears to be a normal component of body fluids which is not expressed 
exclusively under conditions of hypoxia, efforts directed to its identification are 
likely to be complex and extensive, and as such fall outside the scope of the 
present studies. The central question addressed by this research is whether 
MCP-1 is the alveolar macrophage-borne mediator of the systemic inflammation 
of hypoxia. The data strongly support this hypothesis. Within this context, the 
results indicate that a co-factor normally present in biological fluids is necessary 
for physiologically relevant concentrations of MCP-1 to activate mast cells. This 
issue should be considered when analyzing in vitro experiments involving MCP-





4.4.3   Functional relevance of these findings 
  The present and previous studies (Chao et al., 2009a; Gonzalez et al., 2007a) 
highlight the systemic effects of alveolar macrophage activation. In contrast with 
their better know intrapulmonary effects, the extrapulmonary consequences of 
activation of alveolar macrophages have attracted less attention. Recently, 
evidence has been accumulating pointing to a systemic inflammatory effect of 
activation of alveolar macrophages secondary to phagocytosis of inhaled 
particulate matter. Inflammatory mediators released by alveolar macrophages 
enter the circulation to produce inflammation and endothelial dysfunction in 
systemic microvascular beds (Ishii et al., 2005; Nurkiewicz et al., 2006; 
Simkhovich et al., 2008; Tamagawa et al., 2008; van Eeden et al., 2001). It has 
been proposed that these alveolar macrophage-mediated responses underlie the 
elevated cardiovascular morbidity associated with environmental pollution 
(Simkhovich et al., 2008). The phenomenon described in this research 
represents an example of systemic response to alveolar macrophages activated 
by another stimulus, in this case reduced alveolar PO2.    
  Clinical conditions as well as experimental interventions associated with 
alveolar hypoxia are accompanied by systemic effects, and in several of these, a 
systemic inflammatory component has been identified. Examples are the 
sarcopenia and cardiovascular abnormalities of chronic obstructive pulmonary 
disease (Agusti and Soriano, 2008), the insufficient hemopoietic response in 
pulmonary fibrosis (Tsantes et al., 2003b), and the cardiovascular and metabolic 
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dysfunctions in sleep apnea (Jelic et al., 2008). In acute conditions, systemic 
responses with a possible inflammatory link include the multiple organ failure 
secondary to atelectasis (Kisala et al., 1993), acute lung injury (Puneet et al., 
2005; St John et al., 1993) and pulmonary contusion (Perl et al., 2005), the 
systemic inflammation of pneumonia (Fernandez-Serrano et al., 2003) and the 
acute illnesses of high altitude (Basnyat and Murdoch, 2003). It is possible that 
inflammation does not play a causal role in every one of these examples; 
however, it is likely that inflammation modifies their development and outcome. 
The phenomenon described here could play a role in the initiation of the systemic 
inflammation observed in some of these conditions. In this respect, our studies in 
intact animals entailed a fairly severe degree of hypoxia: alveolar PO2 values in 
rats breathing 10% O2 typically decrease to 45-50 Torr. This PO2 is observed, for 
instance, at an altitude of ~ 5,000m, or in clinical conditions in which pulmonary 
function is seriously compromised. However, alveolar macrophage cultures 
released MCP-1 when exposed to a PO2 of ~ 70 Torr and the response to this 
less severe decrease in PO2 was the same as that observed at lower PO2 values 
(Table 2). This would suggest that clinical conditions presenting relatively 
moderate reductions in alveolar PO2 may elicit alveolar macrophage-initiated 
systemic inflammation 
It has been demonstrated that alveolar hypoxia also produces an inflammatory 
response in the lungs, and that alveolar macrophages play an important role in 
this response. Rats breathing 10% O2 show extravasation of albumin and 
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expression of inflammatory cytokines (Beck-Schimmer et al., 2001; Madjdpour et 
al., 2003). These changes are attenuated by the selective depletion of alveolar 
macrophages. In addition, hypoxia induces the expression of neurokinin-1 
receptors in the lung, which in turn lead to inflammatory responses mediated by 
IL-1, IL-6 and TNF-α (Zee et al., 2006). Whether similar mechanisms underlie the 
inflammatory responses of the lung and the systemic circulation to reduced 
alveolar PO2 should be the subject of future research 
Finally, It should be acknowledged, that exposure of an intact organism to 
hypoxia is a complex stimulus which elicits multiple responses. Mechanisms with 
a slower time course, in particular the changes in gene expression initiated by 
the reduction in PO2 are likely to modify the effects of this initial response at later 
times in the course of hypoxia. 
In summary, the present studies provide substantial evidence in support of the 
idea that the systemic inflammatory response to a reduction in alveolar PO2 is not 
initiated by the reduction in PO2 in the systemic microcirculation, but rather by 
activation of mast cells by MCP-1 released by alveolar macrophages and 




Role of renin-angiotensin system in the inflammatory 
response induced by activated mast cells 
5.1   Introduction 
Alveolar hypoxia, induced by 10% O2 breathing, produced an initial arteriolar 
vasoconstriction in skeletal muscle which was followed by vasodilation. Plasma 
from hypoxic rats produced not only increased venular leukocyte-endothelial 
interactions and mast cell activation, but also produced local arteriolar 
vasoconstriction in the normoxic cremaster; both the inflammation and the 
arteriolar vasoconstriction were attenuated by non-selective Ang II receptor 
antagonists and ACE inhibitors (Orth et al., 2005). These agents also prevented 
the inflammation induced by alveolar hypoxia in intact rats (Gonzalez et al., 
2007b). These results suggest a participation of the RAS in the inflammatory 
cascade initiated by alveolar hypoxia. Ang II is a potent vasoconstrictor 
implicated in inflammatory processes in the cardiovascular system. In addition to 
the circulating RAS, local tissue RAS plays an important role in several 
pathophysiological processes, including cardiovascular inflammation (Paul et al., 
2006). Ang II can cause increased leukocyte-endothelial interactions and 
leukocyte recruitment, increased vascular permeability, and eventually tissue 
remodeling (Duprez, 2006; Ferrario and Strawn, 2006). Similar to systemic 
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hypoxia, Ang II stimulates leukocyte-endothelial interactions in postcapillary 
venules via generation of reactive oxygen species (ROS) (Suzuki et al., 2006); 
these effects can be blocked by antioxidant administration (Wood et al., 1999a). 
While Ang II induces inflammation in the normoxic mesentery, it does not elicit 
mast cell degranulation and its effects are not blocked by cromolyn (Piqueras et 
al., 2000). On the other hand, the inflammatory effects of stimulation of mast cells 
with C48/80, a mast cell secretagogue, are attenuated by ACE inhibition and by 
Ang II receptor blockade in cremaster (Gonzalez et al., 2007b). The inflammation 
was not due to increased levels of Ang II or of renin in the donor plasma, 
suggesting that plasma from hypoxic rats activated the tissue RAS, which 
occurred downstream of mast cell degranulation.  
While it is clear that the RAS is activated by mast cells, the underlying 
mechanism is uncertain. Two questions need to be answered: the mechanism of 
formation of Ang II and the origin of renin. There are two possible Ang II 
formation mechanisms by which mast cells may activate the tissue RAS: 
chymase- Ang II forming pathway and ACE- Ang II forming pathway (Akasu et 
al., 1998). The presence of chymase, an angiotensin converting enzyme (Batlle 
et al., 2006; Miyazaki et al., 2006), is species-dependent. A mast cell chymase 
was identified as the major Ang II–forming pathway in the human heart (Urata et 
al., 1990). In rodents, Ang II formation is primarily ACE-related, but chymase 
immunoreactivity is also detected in mast cells (Huntley et al., 1990).  The 
biochemical and physiological roles of chymase seem to vary by subtypes (α and 
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β-chymases) (Sanker et al., 1997). For example, rat chymase I, which was 
identified in rat peritoneal mast cells, belongs to β-chymases subtype and is an 
Ang II-degrading enzyme rather than an Ang II-forming enzyme 
(Chandrasekharan et al., 1996; Le Trong et al., 1987; Sanker et al., 1997). 
However, rat chymase-3, which belong to α-chymases subtype, converts Ang I to 
Ang II by cleaving the Phe8-His9 bond in Ang I (Balcells et al., 1997). Non–ACE-
dependent Ang II formation is also found in rat heart (Balcells et al., 1997; Muller 
et al., 1998), vasculature (Ideishi et al., 1990; Juul et al., 1987; Leite et al., 1997), 
cultured vascular cells, such as endothelial and smooth muscle cells (Andre et 
al., 1990; Ideishi et al., 1993). Previous data from our laboratory suggest that 
hypoxia produced similar inflammatory effects in both mesentery and cremaster, 
including mast cell degranulation, leukocyte-endothelial adhesive interaction. In 
cremaster microcirculation experiments, we observed that topical application of 
Ang II, C48/80 or hypoxic alveolar macrophage supernatant produced similar 
increases in leukocyte-endothelial adhesive interaction (Gonzalez et al., 2007a). 
Ang II receptor blockade and ACE inhibition had essentially the same effects on 
inflammation induced by either alveolar hypoxia or plasma from hypoxic rats 
(Gonzalez et al., 2007b). Since the ACE inhibitors traditionally used do not act on 
mast cell chymase (Fildes et al., 2005; Miyazaki et al., 2006; Takai and Miyazaki, 
2002), these results suggest that conversion from Ang I to Ang II on cremaster 
was entirely due to ACE and not to chymase (Gonzalez et al., 2007b).   
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With respect to the mechanism of activation of the RAS, renin is the enzyme 
that catalyzes the first and rate-limiting step of RAS. Rat cardiac mast cells 
contain renin (Silver et al., 2004) and can release renin to activate RAS under 
conditions of ischemia-reperfusion (Mackins et al., 2006). Whether rat peritoneal 
mast cells contain renin is unknown. 
The aims of the present experiments were two: first, to determine if, as seen in 
skeletal muscle, the RAS is involved in the mesenteric inflammation of hypoxia. 
Similar patterns of inflammation occurring in different vascular beds would be 
consistent with our general hypothesis of an inflammatory response initiated by a 
circulating mediator released by alveolar macrophages. Secondly, we wanted to 
determine if the activation of the RAS by mast cells involves the participation of 
mast cell renin. 
 
5.2  Methods 
The general methods and techniques utilized are described in detail in chapter 2. 
 
5.2.1  Immunocytochemistry  
  Mast cells were resuspended in DMEM to yield cell concentration of 1.25×104 
cells/100μl.  A slide was placed into the slide holder with a slide filter on top. The 
slide funnel was placed onto the slide filter, lining up the holes to make sure that 
the cells would be forced onto the slide. 200μl of the cell suspension containing a 
total of 2.5×104 cells was added to the slide funnel. The lid of the Cytospin was 
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carefully placed over the samples. The slide was spun at 1000 rpm speed for 10 
minutes. 
The slide was placed in methanol at 4°C for 15 minutes, following in 50% 
methanol at room temperature for 10 minutes and PBS at room temperature for 
another 10 minutes. After 3 washes with PBS, the cells were permeabilized for 
30 minutes at room temperature with a solution containing 0.5% Triton X-100 
dissolved in PBS. After 3 washes with 0.5% Triton X-100 dissolved in PBS, cells 
were quenched with 100 mM ammonium chloride for 15 minutes, following with 
3% H2O2 in methanol for 30minutes. After 3 washes with 0.5% bovine serum 
albumin (BSA) / 1% normal goat serum (NGS) in PBS, the slide was blocked by 
using Avidin/Biotin Blocking kit, and then by 1% BSA / 5% NGS in PBS at room 
temperature for 2 hours. Next, the slide was exposed to renin antibody (1:200) in 
0.1% BSA / 2% NGS in PBS at 4°C overnight. Following 3 washes with 0.1% 
BSA in PBS, the slide was exposed to second antibody in 0.1% BSA / 2% NGS 
in PBS for 2 hours at room temperature. After 3 washes with 0.1% BSA in PBS, 
the slide was staining with DAB kit. After washing with water, the slide was 
mounted with PBS kept in 4°C. The slide was examined with a Nikon TE-2000 S 
microscope. 
 
5.3   Results 
5.3.1   Role of the RAS on the response of the microcirculation to hypoxic 
alveolar macrophage supernatant  
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Ang II was selected because of the known participation of RAS (Gonzalez et 
al., 2007b) and mast cells activation (Dix et al., 2003; Gonzalez et al., 2007b; Mc 
Donald and Wood, 2003; Steiner et al., 2003) in inflammation induced by alveolar 
hypoxia. Ang II and C48/80 produced similar inflammatory response in cremaster 
(Gonzalez et al., 2007a). Here, we show that topical application of Ang II (10 nM) 
produced an increase in leukocyte-endothelial adherence without producing mast 
cell degranulation (Figure 12A, N=5). This is consistent with our observation in 
cremaster, which indicates that same mechanism may be involved in the 
widespread inflammation in different microvascular beds.  
Application of supernatant of alveolar macrophages equilibrated with 10% O2 
to the mesentery of rats pretreated with the non-specific Ang II receptor 
antagonist [Sar1,Thr8] Ang II (30 μg/kg/ min , continuously infused i.v. ,Figure 
12B, N=5) or with the NADPH oxidase inhibitor apocynin (1 mM applied topically, 
Figure 12C, N=5) essentially produced the same results: although mast cell 
degranulation occurred in response to the application of supernatant, no increase 




Figure 12  Role of the RAS on the response of the mesentery to hypoxic alveolar 
macrophage supernatant. 
Top: Representative microphotographs of the mesenteric microcirculation after topical application 
of 10 nM Ang II (A), hypoxic alveolar macrophage supernatant in rats pretreated with Ang II 
receptor blocker (B), and hypoxic alveolar macrophage supernatant in rats treated with NADPH 
oxidase inhibitor, apocynin, (C). The red arrows point to the mast cells; the blue arrows identify 
adherent leukocytes. Bottom: average values of leukocyte-endothelial adherence (LEA), 
leukocytes /100 μm, and intensity of mast cell degranulation (MCD) in arbitrary units. C and E: 
mean ± SEM of values at the end of the control and the experimental period, respectively. N=5 in 
all cases. * = P<0.01 vs. corresponding value in intact rats. 
 
Figure 13 shows the effects of Ang II receptor blockade (Figure 13A, N=5) and 
of apocynin (Figure 13 B, N=5) on the response of the microcirculation to the 
basic mast cell secretagogue C48/80. When applied to the mesentery or 
cremaster microcirculation, C48/80 induces mast cell degranulation and 
leukocyte-endothelial adherence. In the present experiments, pretreatment with 
Ang II receptor blocker (Figure 13A) or with apocynin (Figure 13 B) did not 
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prevent the mast cell degranulation but inhibited the leukocyte-endothelial 
adherence induced by C48/80.  
 
  Figure 13 Role of the RAS on the microvascular response to C48/80 
Top: Representative microphotographs of mesenteric microcirculation illustrating the effect of 
topical application of C48/80 after pretreatment with Ang II receptor blocker (A); or with apocynin 
(B). Bottom: average values of leukocyte-endothelial adherence (LEA), leukocytes /100 μm, and 
intensity of mast cell degranulation (MCD) in arbitrary units. C and E: mean ± SEM of values at 
the end of the control and the experimental period, respectively. N=5 in all cases. * = P<0.01 vs. 
corresponding value in intact rats. 
 
These results indicate that, as seen in the cremaster, the increased leukocyte-
endothelial adherence produced in the mesentery by hypoxic alveolar 
macrophage supernatant is mediated by activation of the RAS; the RAS is 
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activated by mast cell degranulation induced, in turn, by an agent released into 
the supernatant by hypoxic alveolar macrophages. The effectiveness of the 
NADPH oxidase inhibitor apocynin on the inflammatory response further 
suggests that the effects of RAS activation are mediated by NADPH oxidase 
assembly. 
 
5.3.2   Peritoneal mast cells contain active renin 
The immunohistochemical results demonstrated that peritoneal mast cells 
express immunoreactive renin which was mainly contained in granules as shown 
in Figure 14B. No immunolabelling was detected in the control group incubated 
with secondary antibody only (Figure 14A). After treatment with mast cell 
secretagogue C48/80, the renin was detected in the granules released from mast 
cells (Figure 14 C). 
 
Figure 14  Presence of renin in rat peritoneal mast cells 
Immnuohistochemical staining with anti-renin antibody was detected in rat peritoneal mast cells 
(B). After activation with mast cells secretagogue C48/80, the renin was detected in the released 





The functional significance of mast cell renin was investigated in the following 
manner. Mast cells were cultured in plasma obtained from normal rats which 
would provide angiotensinogen, the substrate for renin.  MCP-1 was added and 
formation of Ang II was measured by ELISA method. The results showed that 
MCP-1 induced Ang II production in a concentration-dependent manner, which 
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Figure 15  Effect of MCP-1 on the formation of Ang II 
Peritoneal mast cells obtained from normoxic intact rats (0.4×106 cells) were immersed in 0.4 
ml of plasma obtained from normal rat. The plasma contained RS-102895, MCP-1 or both.  Data 




Since degranulated mast cells were the only source of renin, the increased 
formation of Ang II was proportional to the elevated percentage of degranulated 
mast cells, which is confirmed by the evidence that application of renin inhibitor 
(WFML, 3μM) also blocked the formation of Ang II (Figure 16), suggesting the 
renin released from activated mast cells mediated Ang II production.  
























Figure 16 Effect of renin inhibitor on the formation of Ang II  
Peritoneal mast cells obtained from normoxic intact rats (0.4×106 cells) were immersed in 0.4 
ml of plasma obtained from normal rat. The plasma contained renin inhibitor (WFML), MCP-1 or 






5.4  Discussion 
  The central findings of these experiments are the following: 1) topical 
application of Ang II or C48/80 behaved the same way in mesentery as that 
observed previously in the cremaster microcirculation; 2) Ang II receptor blocker 
abolished the inflammatory response induced by either C48/80 or hypoxic 
alveolar macrophage supernatant, which also occurred in cremaster. 3) Apocynin 
blocked the leukocyte-endothelial adherence, but not mast cell degranulation 
induced by either C48/80 or hypoxic alveolar macrophage supernatant. 4) 
Peritoneal mast cells contained renin which was released by degranulated mast 
cells and initiated the activation of local RAS. These findings demonstrate a 
direct link between mast cell degranulation and inflammation induced by 
activation of local RAS. The results add a key piece of evidence that confirms our 
hypothesis that the inflammation produced by alveolar hypoxia is triggered by 
alveolar macrophage-derived MCP-1 via RAS activation. 
The RAS was blocked at two different sites: the interaction between Ang II and 
its receptors and NADPH assembly of NADPH. The Ang II receptor blocker we 
used blocks both type 1 and type 2 Ang II receptors. While most effects of Ang II 
are mediated by type 1 receptor stimulation, there is evidence (Piqueras et al., 
2000) that activation of both receptor types is involved in the increased 
leukocyte-endothelial interactions promoted by exogenous Ang II. Thus, we 
selected an Ang II receptor blocker that would inhibit both type of receptor types.  
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Topical application of supernatant of alveolar macrophages equilibrated with 
10% O2 produced essentially the same response in the mesentery (Chao et al., 
2009a) as that observed previously in the cremaster microcirculation (Gonzalez 
et al., 2007a): mast cell degranulation, increased leukocyte-endothelial 
adherence, and activation of the local RAS. As observed in the cremaster 
(Gonzalez et al., 2007a; Gonzalez et al., 2007b), activation of the RAS in the 
mesentery is a result of mast cell degranulation. Topical application of Ang II 
produced leukocyte-endothelial adherence, but not mast cell degranulation, 
which suggests that the effect of Ang II was downstream of mast cell activation. 
This was confirmed by the treatment of Ang II receptor blocker which abolished 
the leukocyte-endothelial adherence induced by hypoxic alveolar macrophage 
supernatant and C48/80, but not mast cell degranulation. Since alveolar hypoxia 
produced widespread inflammation in different tissues, the same observation in 
mesentery and cremaster support that the similar mechanisms are involved in 
this process.  
In addition to demonstrate the similarity of responses in the cremaster and the 
mesentery, the present experiments expand our previous findings in the 
cremaster by demonstrating a participation of NADPH oxidase in this process:   
topical application of apocynin had essentially the same effects as the Ang II 
receptor blocker in preventing the inflammation induced by both hypoxic alveolar 
macrophage supernatant and C48/80. Previous studies have demonstrated that 
apocynin, an effective and selective inhibitor of NADPH oxidase, inhibited 
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peroxynitrite formation in murine macrophages (Muijsers et al., 2000) and 
vascular cell adhesion molecule 1 (VCAM-1) expression in endothelial cells 
(Matheny et al., 2000), increased glutathione synthesis, activated  activator 
protein 1 (AP-1) in alveolar epithelial cells (Lapperre et al., 1999), and decreased 
the LPS-induced TNF-α expression in human monocytes (Stolk et al., 1994). All 
these properties of apocynin make it a promising anti-inflammatory agent in vivo 
(Zhou et al., 2002). Based upon this series of findings, it provides further insight 
into the mechanism of action of Ang II by showing that its inflammatory effects lie 
downstream of NADPH oxidase activaiton. A role for NADPH oxidase-generated 
ROS has been documented in several conditions characterized by increased 
RAS activity, including diabetes (Li and Shah, 2004), hypertension (Ferrario and 
Strawn, 2006; Hanna et al., 2002), and ischemia-reperfusion (Yusof et al., 2007), 
but the role of ROS in the inflammatory response induced by hypoxia remains 
unclear yet. The dependence of ROS levels on the PO2 was observed in intact 
animals (Wood et al., 1999a), as well as in cardiomyocytes (Duranteau et al., 
1998; Park et al., 1991) and hepatocytes (El-Bassiouni et al., 1998). The extent 
of leukocytes adherence during hypoxia was proportional to the increased in 
ROS level (Steiner et al., 2002). All of those studies suggest the participation of 
ROS in the inflammation induced by the hypoxia. The mechanism of ROS in this 
phenomenon needs further study. 
While it is clear that the RAS is activated by mast cells (Gonzalez et al., 
2007b), the mechanism by which mast cell degranulation activates the RAS was 
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not clear. The traditional RAS is defined by the formation of Ang I from 
angiotensinogen via kidney-derived renin, followed by conversion to Ang II via 
endothelial ACE (Davisson, 2003). Recently, the local generation of Ang II, which 
acts on resident receptor, has gained considerable attention. Renin is the 
enzyme that catalyzes the first and rate-limiting step of RAS. The release of renin 
has been demonstrated in myocardial mast cells (Mackins et al., 2006; Silver et 
al., 2004). Renin mRNA and protein has been detected in fibroblasts, as well as 
endothelial and coronary vascular smooth muscle cells and human mast cell 
lines (Bader et al., 2001; Dostal, 2000; Dostal and Baker, 1999; Endo-Mochizuki 
et al., 1995; Silver et al., 2004). Here, we provided evidence that renin is 
expressed in rat peritoneal mast cells, implying that renin from mast cells 
contributed to activation of tissue-specific RAS in inflammation induced by 
alveolar hypoxia. Furthermore, if MCP-1 is the mediator of inflammation induced 
by alveolar hypoxia, it would be expected that MCP-1 activates the release of 
renin from degranulated mast cells. This appears to be the case: MCP-1 induced 
Ang II production in a concentration-dependent manner, which was blocked by 
pretreatment of MCP-1/CCL2 receptor antagonist. Additional experiments were 
conducted in the presence of 3 µM WFML, a specific rat renin inhibitor, to verify 
that the Ang II-generating activity in the supernatant was indeed renin. The 
results suggest that the formation of Ang II was due to renin because the renin 
inhibitor abolished the increased of Ang II induced by MCP-1.  
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All data in the present experiments suggest that MCP-1 stimulate release of 
renin from mast cells, which, in turn, activates local RAS. However,the signaling 
pathways through which MCP-1 triggers release of renin from mast cells are still 
poorly documented.  The MCP-1 triggers several signal transduction pathway, 
including extracellular signal-related kinases (ERKs) and PI3-kinase (PI3-K) 
pathway (Cambien et al., 2001). The pathway involved in our case need further 
studies. 
  In summary, the present experiments provide key evidence in support of our 
hypothesis that the inflammation of alveolar hypoxia is initiated by the release of 
MCP-1 from alveolar macrophages. MCP-1, in turn, induced Ang II production 
which was inhibited by CCL2 receptor antagonist and rennin inhibitor, indicating 





Summary of findings and future directions 
6.1  Summary of major findings 
The central findings of this project are the following: 1) There is a direct link 
between alveolar macrophage activation by hypoxia and mast cell degranulation. 
The results also rule out the possible role of low tissue PO2 on the resident tissue 
macrophages or tissue mast cells in the early phase of the inflammation of 
alveolar hypoxia. 2) MCP-1 plays a central role in the initiation of the systemic 
inflammatory response to alveolar hypoxia. A co-factor, normally present in 
normoxic plasma and originated in alveolar macrophages, is necessary for the 
stimulatory effect of MCP-1 on mast cells. 3) Mast cell-derived renin initiates the 
activation of local RAS which mediates the inflammation induced by alveolar 
hypoxia.  
First, supernatant of hypoxic alveolar macrophages elicited an inflammatory 
response in the normoxic mesentery, while supernatant of peritoneal 
macrophages equilibrated with even lower PO2 values had no inflammatory 
effect. On the other hand, alveolar macrophages, but not peritoneal 
macrophages responded with a transitory release of H2O2 when exposed to 
hypoxia. The H2O2 release is a manifestation of the respiratory burst which 
occurs during macrophage activation and is characterized by superoxide 
generation followed by dismutation to H2O2. Mast cell degranulation did not occur 
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when mast cells were directly exposed to hypoxia for a period consistent with the 
time course of the initiation of the inflammation; however degranulation was 
observed when the mast cells were immersed in supernatant of alveolar 
macrophages that had been equilibrated in hypoxia. Thus, both in vivo and in 
vitro findings demonstrate a link between activation of alveolar macrophages by 
hypoxia and mast cell degranulation. These results also show that neither 
reduced local PO2 nor activation of resident tissue macrophages participate in 
the initiation of the systemic inflammation of hypoxia.  
Second, primary cultures of alveolar macrophages, but not of peritoneal mast 
cells or peritoneal macrophages, released MCP-1 within 30 minutes of exposure 
to hypoxia. Plasma MCP-1 levels in conscious rats breathing 10 % O2 increased 
during the first 30 minutes of hypoxia; this increase was abolished by depletion of 
alveolar macrophages. Immersion of mast cells in the plasma drawn from the 
intact conscious rats breathing 10% O2, in which an elevated MCP-1 level was 
documented, produced substantial degranulation, while degranulation did not 
occur when mast cells were immersed in plasma of alveolar macrophage-
depleted rats, which had lower MCP-1 concentration. A role of MCP-1 in the 
systemic inflammation of hypoxia in the intact animal was further supported by 
the observation that pretreatment of the mesentery with RS-102895, a selective 
antagonist for CCR2b (the putative MCP-1/CCL2 receptor expressed in mast 
cells), prevented the rapid degranulation of perivascular mast cells and the 
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increased leukocyte-endothelial adherence to mesenteric venules which was 
observed in intact rats breathing 10% O2.  
Addition of MCP-1 to normoxic plasma or normoxic alveolar macrophages 
supernatant produced concentration-dependent degranulation of immersed mast 
cells. The percent of degranulated mast cells immersed in the plasma samples 
drawn from the intact rats breathing 10% O2 was close to that seen when mast 
cells were immersed in normoxic plasma or normoxic alveolar macrophages 
supernatant with similar MCP-1 concentrations (Figure 8). These results indicate 
that the plasma MCP-1 level reached by the hypoxic rats with normal alveolar 
macrophages count is sufficient to induce mast cell degranulation, suggest that 
mast cell degranulation occurred as a result of the elevated MCP-1 
concentration, and was not the result of other factors associated with hypoxia. 
The possibility of a co-factor was initially suggested by the observation that 
MCP-1 did not produce degranulation of mast cells immersed in normoxic cell 
culture medium, even at concentrations that were effective in plasma or in 
alveolar macrophage supernatant. The results of the filtration experiments 
suggest that the co-factor was composed of at least two fractions: one with a 
molecular weight between 30 and 50 kDa and the other with a molecular weight 
between 50 and 100 kDa. The co-factor is constitutively secreted by alveolar 
macrophages and is normally present in plasma and extracellular fluid, which is 
suggested by several lines of evidence: 1) mast cells immersed in plasma 
obtained from alveolar macrophage-depleted rats after 60 min of 10 % O2 
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breathing did not undergo degranulation. This was in spite of the fact that this 
sample exhibited a MCP-1 concentration that produces degranulation of 40-50 % 
of mast cells immersed in plasma from intact rats or in alveolar macrophages 
supernatant;  2) topical MCP-1 dissolved in serum-free DMEM replicated the 
response to hypoxia in the mesentery of intact, normoxic rats, while it had no 
effect in the alveolar macrophage-depleted rats; 3) MCP-1 dissolved in plasma of 
rats with normal alveolar macrophages count did produce an inflammatory 
response in the alveolar macrophages –depleted rats. Although these results 
provide persuasive evidence of an alveolar macrophage-borne co-factor of MCP-
1, further study will be needed to dissect its exact nature 
Third, Ang II induced leukocyte-endothelial adherence without producing mast 
cell degranulation, which suggest that activation of RAS occurs downstream of 
mast cell degranulation. Ang II receptor blocker inhibited the leukocyte-
endothelial adherence, but not mast cell degranulation induced by either hypoxic 
alveolar macrophage supernatant or C48/80, which suggest that inflammatory 
response is mediated by RAS. The source of rennin was peritoneal mast cell as 
confirmed by immunocytochemistry. Renin released from the degranulated mast 
cell in turn activated local RAS, which initiated a cascade of events resulting in 
the local inflammatory response. 
In summary, the present studies provide substantial evidence in support of the 
idea that the systemic inflammatory response to alveolar hypoxia is initiated by 
an alveolar macrophage-borne mediator, which, in turn, activate mast cells and 
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local RAS. The results also provide compelling evidence that this mediator is 








6.2  Future directions 
The key finding of the current experiments is that MCP-1 released from 
alveolar macrophages initiates the cascade of inflammation. The time course of 
release of MCP-1 suggests that this is not due to changes in gene expression of 
MCP-1. It is likely that MCP-1 stored in alveolar macrophages is released in 
response to the stimulation of hypoxia. The mechanism by which hypoxia triggers 
the release of MCP-1 from alveolar macrophage is not clear. On the other hand, 
hypoxia may induce release of MCP-1 from other type cells, which is suggested 
by the observation that the level of MCP-1 increased in plasma from alveolar 
macrophage-depleted rats exposed to 10% O2 for 60 minutes. The stimulus, as 
well as the role of the delayed release of MCP-1, is not known. Interestingly, this 
plasma did not induced mast cell degranulation in vivo, while the MCP-1 
dissolved in normoxic plasma or alveolar macrophage supernatant in the same 
concentration induced mast cell degranulation. These results suggest the 
existence of co-factor in normoxic plasma or alveolar macrophage supernatant 
for effect of MCP-1 on mast cells. Further experiments will be undertaken to 
identify the nature of the candidate co-factor. 
MCP-1 activated mast cells either in vivo or in vitro system, which is mediated 
primarily through its cognate receptor, CCR2, expressed in mast cells. Pathways 
triggered by MCP-1 include the following: induction of a pertussis toxin (PTX)-
sensitive rise of intracellular calcium, inhibition of adenyl cyclase, phospholipase 
C activation, activation of extracellular signal-related kinases (ERKs), stimulation 
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of 2 separate PI 3-kinase isoforms, namely p85/p110 PI3-kinase (PI3-K) and 
PI3K-C2α. However, which signal transduction pathway is involved in mast cell 
degranulation induced by alveolar macrophage-derived MCP-1 remains unknown 
and need further investigation. 
Previous and current studies in cremaster and mesenteric microcirculation 
suggest the participation of RAS in inflammation induced by alveolar hypoxia.  
There are two possible mechanisms by which mast cells may activate the RAS: 
chymase- Ang II forming pathway and ACE- Ang II forming pathway. Both ACE 
inhibition and Ang II receptor blockade attenuate the inflammatory effects in 
cremaster microcirculation induced by either hypoxia or mast cell secretagogue 
C48/80, which suggest that the ACE-Ang II forming pathway plays a role in the 
cremaster microcirculation bed. Whether the ACE-Ang II forming pathway plays a 
same role in other types of microcirculation bed, such as mesenteric 
microcirculation, remains poorly defined. We have shown that renin inhibitor 
blocked the formation of Ang II induced by MCP-1 in cultured mast cells. The 
experiments carried out in mast cells with ACE inhibitor will help to answer this 
question. 
Moreover, previous and current studies suggest that mast cell degranulation is 
a key event in the inflammation induced by alveolar hypoxia. Mast cells are 
abundant in the microcirculatory beds in which the inflammatory effects of 
hypoxia have been demonstrated. Mast cells are known to degranulate and 
release various inflammatory mediators that are either preformed, such as 
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histamine, proteoglycans, and tryptase, or synthesized, including leukotriene B4, 
platelet activating factor, prostaglandins, and cytokines, some of which have 
been shown to participate in the systemic inflammation of hypoxia, such as 
leukotriene B4 and platelet activating factor. Whether other products released 
from degranualted mast cells are involved in the inflammation induced by 
hypoxia will be subject to further study. 
In summary, the present experiments provide strong evidence to support our 
hypothesis that the mediator released from alveolar macrophage initiates the 
cascade of inflammation by activation of mast cells and local RAS. The proposed 
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